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Abstract 
 
This research sets out to build upon excited state o-azaxylylene cycloaddition.  
The mechanism behind the excitation and cycloaddition process of photogenerated o-
azaxylylenes was determined experimentally.  Time-correlated single-photon counting, 
steady-state spectroscopy, triplet quenching experiments, and quantum yield studies 
provided evidence suggesting that excited state intramolecular proton transfer is followed 
by intersystem crossing and stepwise addition to the tethered unsaturated pendant. 
In keeping with the principles of diversity oriented synthesis, a modular approach 
was taken to gain access to a diverse array of N,O,S-Polyheterocycles which were 
modified postphotochemically via Suzuki coupling to yield fused biaryls.  Cycloaddition 
products, outfitted with halogens in the aromatic ring of the o-azaxylylene, proved to be 
reactive with a variety of boronic acids resulting in a rapid growth in structural 
complexity. 
A novel procedure was developed that utilized multiple o-azaxylylene cores in a 
photochemical cascade transformation yielding complex scaffolds of unprecedented 
topology.  The photoprecursors were produced in a one-pot two-step sequence from 
commercially available starting materials, and upon irradiation yield structures containing 
up to five fused hetrocyclic rings, and showed complete diastereoselectivity. 
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Chapter One: Introduction 
In 2014 $373.9 billion was spent on prescription drugs in the U.S. alone, an 
increase of 13.1% ($43.4 billion) from the previous year.
1
  Per capita spending in 2014 
almost tripled since 1995, an increase from $339 to $995 when adjusted to 2005 dollars, 
and record spending on new brands was observed, totaling $20.2 billion, tripling that in 
2013.
1
  This recent upward trend in pharmaceutical spending has been driven by an 
increased emphasis on healthcare in the United States.  In 2014 15.7 million people 
gained health insurance coverage as a result of the Affordable Care Act, and  patients 
filled prescriptions 25.4% more often in states with expanded Medicaid eligibility.
1
  
Given the growing demand for healthcare, there is a substantial amount of funding that 
goes into the research and development for the industry.  Approximately $30.3 billion in 
funding is supplied by the National Institute of Health annually to medical research,
2
 and 
R&D spending by the pharmaceutical industry totaled $51.1 billion in 2013.
3
  Given the 
large investment into the pharmaceutical industry, as well as the amount of time and 
effort spent producing new drugs, it’s staggering to see just how few new active 
substances are introduced on an annual basis. 
At the time this document was written, the CAS registry just reached a 100 
million compounds,
4
 the majority being small molecules,
5
 and annually over 4 million 
new compounds are submitted; however, only 42 New Active Substances were 
  2 
introduced in 2014, the most since 2001.
1
  The stark contrast between the number of 
compounds submitted to the CAS registry and the number of new active substances is 
striking.  One possible explanation is the obvious discrepancy between the structure of 
new active substances and those synthesized in the laboratory.  Szychowski et al. 
emphasize that “despite the prevalence of combinatorially derived libraries in the 
pharmaceutical industry,” from January 1981 to December 2010, over half of new active 
drugs were either natural products (NP) or derivatives,
6
 and  
when compared to compounds prepared by combinatorial approaches, NPs tend to 
(a) have more stereogenic centers, (b) have a larger fraction of sp
3
 carbons, (c) be 
less hydrophobic, (d) have more oxygen atoms, (e) have fewer nitrogens, sulfurs, 
and halogens, (f) have fewer rotatable bonds, (g) have more fused, bridge, and 
spiro rings, and (h) have more solvated hydrogen bond donors and acceptors.
6
   
 
Combinatorial chemistry further compounds the problem, as this methodology yields 
structurally similar products by design, ignoring a vast and unexplored region of 
chemical space.  Half of the compounds submitted to the CAS registry contain one of 143 
basic frameworks,
7
 and this lack of structural diversity can partially be attributed to the 
synthetic cost of developing new molecular architecture,
7
 as modifications to the core 
framework pose a greater synthetic challenge than modifying the perimeter of an 
established scaffold.  
Given the amount of time and money, as well as the importance of healthcare, it is 
disturbing to see a trend where many compounds synthesized by combinational 
methodology lack structural diversity and do not conform to the trends put forth by the 
body of data which support biological activity.  To address this issue, new approaches 
and a greater amount of structural diversity must be incorporated into scientific 
  3 
methodology in the future.  The research within this dissertation focuses on the 
photochemical transformations of o-azaxylylenes which yield complex structures of 
unprecedented topology containing multiple fused rings, chiral centers, a high degree of 
saturation, and few rotatable bonds, all of which are characteristic of natural products.  
Below (Scheme 1.1) is a representative example, from the research presented in this 
dissertation, of the spectacular growth of complexity which can be generated in three 
steps, from affordable starting materials, and obtained in high purity without column 
chromatography.  This methodology is based on diversity oriented synthesis, an approach 
that probes a greater region of chemical space when compared to conventional 
combinatorial methods. 
 
 
Scheme 1.1  
 
Synthetic Methodology 
Chemical space is an abstract idea that places all possible molecules in a 
multidimensional coordinate system according to their structure and physical properties.  
Reymond et al. explains chemical space as a “geographical map to illustrate the 
  4 
distribution of molecules and their properties,”8 notes that there are thousands of different 
descriptors, and as a result many dimensions from which this map can be derived, 
“including atom and bond types, polar groups, and topological features.”  It is the 
unexplored region of chemical space where new drug discovery takes place, and there are 
three general approaches to small molecule synthesis, all of which sample a different 
region of this chemical space: target oriented synthesis (TOS), combinatorial chemistry, 
and diversity oriented synthesis (DOS).
9
 
TOS is a process that aims to synthesize a specific compound, usually a natural 
product, which is known to have a desired biological activity.  This approach is (i) based 
on a retrosynthetic methodology, (ii) only aims to synthesize one specific compound, and 
as a result (iii) only probes one coordinate of chemical space.  Combinatorial chemistry 
differs from TOS in that it aims to decorate a known biologically active core scaffold 
with various functional groups leading to a library of new compounds.  This methodology 
probes a greater region of chemical space than TOS, but is somewhat restricted in the 
region of chemical space that it explores given the conservation of the core scaffold.  
DOS is a forward-thinking methodology that aims to probe the largest region of chemical 
space possible, in that multiple modifications are performed throughout the synthesis, 
including that of the core scaffold, producing a large number of significantly diverse 
compounds.   
A famous example of target oriented synthesis is Taxol
® 
(Figure 1.1), an 
anticancer drug that was initially isolated as a natural product from the Pacific yew tree 
(Taxus brevifolia).
10
  Harvesting the drug from natural sources was impractical, as 38,000 
  5 
Taxus brevifolia trees would be needed to yield just 25 kg of Taxol
®
, and three trees 
would be needed to treat one person. 
 
 
Figure 1.1 
 
 It took around two decades for a total synthesis to be accomplished given the 
complexity of the molecule, as it contains a complex 6:8:6 fused ring system, 11 chiral 
centers, and is densely populated with various functional groups.
10
  One of the first total 
synthetic pathways, developed by Nicolaou et al., was accomplished in 51 steps with an 
overall yield of 0.4%.
11
  Total synthesis is important, as the process often advances 
synthetic methodology, and there may be no other way to access these valuable scaffolds.  
However, when searching for new biologically active drugs, it’s vital to probe the 
greatest region of chemical space possible.  Both combinatorial chemistry and diversity 
oriented synthesis are valuable tools, as they are capable of producing large libraries of 
compounds efficiently.  A forward thinking DOS philosophy should be implemented in 
conjunction with combinatorial chemistry to probe the greatest area of chemical space 
possible in hopes to find new drug candidates. 
The principal concept behind diversity oriented synthesis is to efficiently produce 
a large library of compounds that are significantly different from one another so that a 
  6 
greater region of chemical space can be explored.  To do this, multiple modifications are 
performed after each step in the sequence resulting in the multiplicative growth of diverse 
compounds resulting from the synthesis.  At each stage stereocenters, appendages, and 
modifications to the core framework can be introduced.  An example of DOS can be seen 
in Scheme 1.2, which is centered around o-azaxylylene photochemistry and is an excerpt 
from the research presented in this dissertation.
12
 
 
  7 
 
Scheme 1.2 
  8 
Peripheral decoration of a core scaffold with functional groups is common place 
in combinatorial chemistry, as the core scaffold remains the same
9
, and there are many 
examples of this in Scheme 1.2, such as the addition of benzylamine or furfuryl amine  
However, the most significant transformation can be seen when the overall topology 
changes in the core framework, the cornerstone of DOS, which occurs upon irradiation 
yielding significantly different [4 + 4] and [4 + 2] isomers.  Not only does this irradiation 
produce diverse scaffolds, but it also introduces 3 stereocenters, and some of the resultant 
assemblies contain fragments that are found in active pharmaceuticals, such as a fused 
2,5-diketopiperazine ring.  This fragment is the core template in many bioactive 
molecules (Figure 1.2), such as PDE-5 inhibitors (Cialis), preterm labor drugs 
(Retosiban), various cancer inhibitors (Phenylahistin), and “are among the most 
numerous of all naturally occurring peptide antibiotics.”13 
 
 
Figure 1.2 
 
In keeping with the principles of DOS, further modifications to the synthetic 
methodology behind o-azaxylylene photochemistry have been implemented by various 
  9 
members of Dr. Kutateladze’s lab yielding structurally diverse scaffolds,14-16  and a small 
subset can be seen in Figure 1.3.   
 
 
Figure 1.3 
 
 All the above examples were synthesized by utilizing intramolecular addition to 
o-azaxylylenes in the excited state, and it should be clear just by looking at Figure 1.3 
that this methodology is a powerful technique capable of yielding significantly distinct 
topologies in keeping with the fundamentals of DOS. 
  
o-Azaxylylenes 
o-Azaxylylenes (1.1a) have been explored for over half a century, and throughout 
their history have been utilized as unstable heterodiene intermediates in a few [4 + 2] 
cycloaddition reactions with only a handful of dienophiles (Scheme 1.3).
17
   
 
  10 
 
Scheme 1.3 
 
Prior to 2011, approaches to the in situ generation of o-azaxylylenes could be 
broken down into six categories (Scheme 1.4); nitrene formation followed by a [1,4]-
hydrogen shift (1.1b), valence isomerization of strained benzoazetines (1.1c), thermal 
cheleotropic extrusion of SO2 (1.1d) or CO, [4 + 2] cycloreversions (1.1e), ring-opening 
of heterocyclic systems (1.1f), and elimination (1.1g).
17
  
 
 
Scheme 1.4 
  11 
 
One thing that should be noted when looking at Scheme 1.4 is that the conditions 
are typically harsh, requiring high temperatures or even flash vacuum thermolysis (FVT), 
and as a result are not compatible with many substrates.  Before 2011 there were few 
examples of dieneophiles outside of N-phenylmaleimide (NPMI), or basic alkenes and 
alkynes that were reactive with the o-azaxylylene core.
17
  Below (Scheme 1.5) is the 
synthetic sequence used by Burgess and McCullagh to trap an o-azaxylylene intermediate 
with NPMI, which is also the first experimental proof of o-azaxylylene formation.
18
 
 
 
Scheme 1.5 
 
Though most of the methods in Scheme 1.4 are harsh, special attention should be 
paid to the synthesis utilizing substrate 1.1g, which “involves base-induced elimination of 
hydrogen chloride from amide or sulfonamide derivitives,”19 and was thought at the time 
to be “the simplest method possible for o-azaxylylene production …”  Steinhagen and 
Corey demonstrated that this methodology can be used for intermolecular and 
intramolecular [4 + 2] cyclization of electron rich olefins without the need for drastic 
conditions, allowing access to a handful of unique structures including the core scaffold 
of virantmycin, an antiviral agent, as a racemic mixture in respectable yields (Scheme 
1.6). 
  12 
 
 
Scheme 1.6 
 
 On paper this method for generating o-azaxylylenes looks simple; however, the 
actual process is not without its difficulties.  Synthesis involves the addition of the 
cholormethylaniline derivative to the base and diene by syringe pump over, and 
depending on the substrate this can take up to 24 hours while maintaining a temperature 
as low as -78 °C.
19
 
   
Photogenerated o-Azaxylylenes 
For ten years Steinhagen and Corey’s19 methodology would stand as the only 
viable way to utilize azaxylylenes synthetically, until 2011 when Mukhina et al., a fellow 
group member, reported the first example of [4 + 2] and [4 + 4] cycloadditions stemming 
from the excited state intramolecular proton transfer (ESIPT) of photogenerated o-
azaxylylenes in the formation of complex N,O,S-Polyheterocycles.
20
  This novel 
approach is advantageous over the preceding methodology, as it eliminates the need for 
harsh conditions or reagents that may not be accommodating to substrates. The 
irradiation process is about as simple as flipping a switch, and allows access to [4 + 4] 
cycloaddition products, a process that is forbidden in the ground state, in addition to the 
[4 + 2] cyclization products.  A representative from the work of Mukhina et al. is 
  13 
depicted in Scheme 1.7.  This simple synthetic sequence involves coupling 2’-
aminoacetophenone with the acyl chloride produced from 3-(2-furyl)propionic acid, and 
subsequent irradiation of the photoprecursor (1.2) yielding the [4 + 2] (1.3), and [4 + 4] 
(1.4) cycloaddition products in only three steps.  Given the simplicity of this method it is 
staggering that it had not been discovered earlier, and the authors note that “it is 
conceivable that [photochemical generation of azaxylylenes] was attempted but failed 
due to the back proton transfer successfully competing with bimolecular 
cycloadditions.”20 
 
 
Scheme 1.7 
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Multiple diversity inputs can be introduced under these reaction conditions 
(Scheme 1.8).  Tethered alkenes, furan, and thiophene pendants proved to be reactive 
dienophiles, as o-azaxylylenes act as acceptors in inverse electron demand 
cycloadditions. The tether could be three to four atoms in length, respectively producing 
five and six membered rings upon irradiation.  Aldehydes, ketones, and cyclic ketones all 
proved to be reactive.   
 
 
Scheme 1.8 [Adopted From Angew. Chem. Int. Ed.
20
]  
 
Photoprecursors showed broad UV absorption, with a maximum between 340-350 
nm, and were irradiated using 365 nm Nichia UV LEDs or a Rayonet broadband 300-400 
nm UV source yielding [4 + 2] and [4 + 4] isomers in most cases.
20
  An overview of the 
first series of reactions run by Mukhina et al. can be seen in Scheme 1.9.  Not only were 
the products obtained in high overall yields, ranging from  60-89%, high 
diastereoselectivity of the hydroxyl group relative to the bridged heteroatom was 
observed in most cases.  The anti diastereomer predominated in the [4 + 2] 
  15 
cycloadditions while syn predominated in [4 + 4] cycloaddition, and in most cases 
the diastereomeric ratio was 30:1 for the aldehydes.20    
 
 
Scheme 1.9 [Adopted From Angew. Chem. Int. Ed.
20
] 
 
It was postulated that this selectivity was the result of an endo transition state for 
both the [4 + 2] and [4 + 4] cycloadditions (Scheme 1.10), where the resulting isomer is 
dictated by the direction the hydroxyl group is facing in the transition state.
20
  Tetralone 
is incapable of rotation at the carbonyl, and ketones are sterically hindered in the out-
hydroxy conformer and as a result show exclusive selectivity. Aldehydes show minor 
  16 
amount of the unfavorable diastereomer, as they are less sterically hindered in the out-
hydroxy conformer when compared to the ketones. 
 
 
Scheme 1.10 [Adopted From Angew. Chem. Int. Ed.
20
] 
 
  17 
 The research put forth in the following chapters of this dissertation sets out to 
build upon the body of research by this initial discovery. In the following chapters, 
evidence will be presented confirming that these cyclizations occur in the triplet excited 
state in a stepwise fashion; that these photoproducts, and precursors can be modified in 
keeping with the principle of diversity oriented synthesis; and build upon the 
methodology by giving the first example of an excited state cascade reaction involving 
two consecutively photogenerated o-azaxylylenes.  
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Chapter Two: Mechanistic Studies 
Of all the things that I have accomplished at the University of Denver it is the 
work in this chapter that I take the most pride in.  Many novel compounds and diverse 
libraries have come out of our lab, but this research was special to me because it was 
about finding an answer.  Understanding the underlying photophysics and 
photochemistry behind excited state o-azaxylylene cycloadditions will optimize future 
approaches to this methodology.  However, this project felt like I was doing science for 
science’s sake, and there is something special about doing something for its intrinsic 
value. 
 
Introduction  
When Mukhina et al. published their initial work on photogenerated o-
azaxylylenes “a detailed photophysical mechanistic study of these cycloadditions [was] 
ongoing;”20 however, there were some indications that the reaction occurred in a stepwise 
fashion.  First, concerted [4 + 2] cycloaddition is not allowed in the excited state, but 
occurs upon coupling photogenerated o-azaxylylenes with tethered dienophiles, and the 
only way that this can occur in the excited state is if the addition occurred in a stepwise 
fashion.  This is best demonstrated using frontier molecular orbital theory (Scheme 2.1), 
where the highest occupied molecular orbital (HOMO) must share the same symmetry 
  19 
with the lowest unoccupied molecular orbital (LUMO).  If this process is concerted an 
overlap in symmetry must occur for an overall net bonding interaction; however, there is 
an asymmetrical overlap between the orbitals for [4 + 2] cyclization in the excited state 
ruling out a concerted process.  For clarity, the [4 + 4] cyclization is also depicted, which 
is allowed in the excited state but forbidden in the ground state according to the frontier 
molecular orbital theory.  
 
  20 
 
Scheme 2.1 
 
Another piece of evidence suggesting that the mechanism is not concerted was the 
formation of disproportionation products (Scheme 2.2) that could only occur if the 
reaction proceeded in a stepwise fashion.  If the excited state o-azaxylylene is depicted as 
a diradical, the mechanism can be initiated with an N-centered radical attack  
  21 
on the double bond to form the initial 1,6-diradical, which can (i) rotate its 
benzylic center and recombine to form the [4 + 2] adducts, or (ii) disproportionate 
by H-abstraction to form benzylic alcohol with an N-acyl enamine moiety, which 
undergoes subsequent ground state or photoinduced intramolecular alcohol 
addition to yield aminal 2.1 (17%).
20
  
 
 
Scheme 2.2 [Adopted From Angew. Chem. Int. Ed.
20
] 
 
The following study was performed to elucidate the mechanism behind the 
intramolecular cyclization of photogenerated  o-azaxylylenes and was published in the 
Journal of Physical Chemistry A.
21
  Quantum yields, quantum efficiency in the presence 
of triplet quenchers, steady state spectroscopy, and time-correlated single photon 
counting were used to provide a significant body of evidence that the excited state 
intramolecular proton transfer (ESIPT) is followed by intersystem crossing (ISC) to the 
triplet state, and stepwise addition to the tethered unsaturated pendant.   
Results and Discussion 
From a mechanistic standpoint, there are several potential pathways that 
photogenerated o-azaxylylenes can take to yield intramolecular cycloaddition products 
(Scheme 2.3).  This pseudo Jablonski diagram does not depict the relative energies of 
each species, but instead is designed to be a tool to help envision the possible routes that 
  22 
can be taken to reach the cyclization products.  The possibilities listed in Scheme 2.3 can 
be ruled out systematically.  Pathway 1 and 2 involve cycloaddition in the ground state, 
and evidence will be presented against this process.  Pathway 3 does not undergo 
intersystem crossing (ISC), and can be eliminated by providing evidence that the reaction 
proceeds through a triplet state.  The final two pathways, 4 and 5, both proceed through a 
triplet state and only differ where the excited state intramolecular proton transfer (ESIPT) 
takes place, and this difference can be addressed through phosphorescence studies.
22
 
 
  23 
  
Scheme 2.3 
 
  24 
The first two potential pathways listed involve cycloaddition in the ground state, 
and both can be addressed simultaneously.  Pathway 1, involves a pure ground state 
reaction leading to the cycloaddition products, and pathway 2 proceeds through excitation 
to the first singlet excited state (S1), ESIPT, internal conversion to a ground state o-
azaxylylene, and cycloaddition.  According to DFT calculations, there is no energy 
barrier for the back proton transfer in the ground state (Figure 2.1), indicating that o-
azaxylylene formation in the ground state is not favorable as the cycloaddition process 
could not compete with the rate of back proton transfer, ruling out pathway one.  There is 
an energy barrier for the back proton transfer in S1, so the lifetime of the o-azaxylylene 
would be significantly greater in S1 than in the ground state.  However, a ground state 
cycloaddition mechanism after excitation, ESIPT, and internal conversion to the ground 
state, pathway two, is unfavorable.  Internal conversion of an o-azaxylylene from S1 to 
the ground state would result in an immediate back proton transfer, as there is no energy 
barrier in the ground state, which is significantly faster than the cycloaddition process. 
 
  25 
 
Figure 2.1 [Adopted From J. Phys. Chem. A
21
] 
 
 Knowing that the cycloaddition takes place in the excited state, the next question 
to answer is if the excited state species remains as a singlet, or undergoes intersystem 
crossing (ISC) to a triplet state.  Without ISC to the triplet state, the underlying process 
could potentially proceed through excitation to S1, followed by ESIPT, cycloaddition, and 
internal conversion to the ground state yielding the cycloaddition products, Pathway 3.  A 
significant body of evidence has been generated to leave little, if any, doubt that the 
mechanism proceeds through a triplet state. 
 To start, the quantum efficiency of cyclization significantly decreases upon the 
addition of known triplet quenchers, trans piperylene
23
 and molecular oxygen (Figure 
2.2).  Not only does this provide insight to the photochemical process, but allows for the 
calculation of the excited state species lifetimes using Stern-Volmer analysis (KSV = 99 
  26 
for quenching with O2 in acetonitrile, and KSV = 57 for quenching with trans-piperylene 
in benzene).  Assuming that the rate of quenching is diffusion controlled (Kdif = 1.0 x 
10
10
 M
-1
 s in benzene, and 1.9 x 10
10 
in acetonitrile
24
), the lifetime of the excited triplet 
state species for 2.1b was calculated to be approximately 5.2 ns in acetonitrile and 5.7 ns 
in benzene. 
   
 
 
Figure 2.2 [Adopted From J. Phys. Chem. A
21
] 
 
 Further evidence supporting a triplet state mechanism was provided by time 
correlated single photon counting (TCSPC) experiments (Figure 2.3), which were 
performed on o-azaxylylene photoprecursors bearing furan pendants (2.1a and 2.1b), and 
their acetylated counterparts (2.11a and 2.11b).  It is difficult to determine the identity of 
each species.  However, the results indicate that the addition of a furan pendant does not 
have an effect on the rate of decay of fluorescence.  If the mechanism proceeded through 
  27 
a singlet state, the fluorescence lifetime of the ESIPT singlet state species would decrease 
upon substituting the acetyl group with the furan pendant, as there would be an 
alternative pathway taking away from the quantum yield (QY) of fluorescence.  We do 
not see this when comparing the furanpropanoylated and acetylated pairs, leading to the 
conclusion that the reaction likely proceeds through a triplet state. 
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Figure 2.3 [Adopted From J. Phys. Chem. A
21
] 
 
 Additional evidence supporting a triplet state mechanism can be seen when 
comparing the fluorescence spectrum of o-azaxylylene photoprecursors with differing 
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pendants and substitutions.  o-Azaxylylenes produce two distinct bands, usually between 
350 and 650 nm, where the blue shifted band represents the fluorescence of the excited 
ketone or aldehyde where no ESIPT has taken place, and the red shifted band 
representing that of the ESIPT species
25
.  When comparing the fluorescence spectrum of 
the aminotetralone derivative bearing a reactive furan pendant, 2.4a, to that of the 
acylated species incapable of cycloaddition, 2.12a one can see that there is little 
difference in the relative intensities between the two bands in the fluorescence spectra 
(Figure 2.4).  The rationale is similar to that in the TCSPC experiment: if there were a 
cycloaddition channel in the singlet excited state then a decrease in fluorescence emission 
of the red-shifted band should be observed for the species capable of cycloaddition, 2.4a, 
when compared to that of the species incapable of cycloaddition, 2.12a.  Solutions of 
2.4a or 2.12a (1x10
-5 
M in DCM) were irradiated at 325 nm. 
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Figure 2.4 [Adopted From J. Phys. Chem. A
21
] 
 
 Halogen substitution in the aromatic ring produces a significant change in the 
ratio between the fluorescence intensity of the two bands.  This can be seen when 
comparing the tetralone derivative bearing a reactive furan pendant (2.4a) to the same 
species with a bromo substitution in the para position (2.2b, Figure 2.5).  Heavy atoms, 
in this case bromine, have a high nuclear charge and cause electrons to accelerate as they 
pass by the nucleus increasing the rate of spin-orbit coupling-induced transitions, which 
is necessary for intersystem crossing (ISC) from a singlet to a triplet state.
24
  This 
phenomenon, dubbed the “heavy atom effect,” manifests itself in Figure 2.5 as a 
decrease in the fluorescence intensity of the ESIPT band upon bromo substitution that 
results from an increased quantum yield of ISC. 
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Figure 2.5 [Adopted From J. Phys. Chem. A
21
] 
 
An absolute quantum yield study was performed on a library of o-azaxylylene 
photoprecursors using a benzophenone-benzhydrol actinometer
26
 (Figure 2.6).  Solutions 
of the photoprecursor (1x10
-2 
M) in acetonitrile were thoroughly degassed with N2, 
irradiated on a carrousel using 365 nm Nichia UV LEDs along with the actinometer, and 
the formation of the [4 + 2] and [4 + 4] cycloaddition products in the samples being 
tested, as well as the formation of pinacol in the actinometer were monitored by 
1
H 
NMR.  In keeping with the heavy atom effect, photoprecursors containing halogen 
substituents had significantly greater quantum yields than their non-halogenated 
counterparts.  Substitution at the carbonyl impeded the cycloaddition process, which can 
be attributed to the stabilized hydroxybenzylic radical being less reactive.  
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Figure 2.6 [Adopted From J. Phys. Chem. A
21
] 
 
The greatest quantum yield in the series was the aminobenzaldehyde derivative 
containing a bromo substitution at the 5 position (Φr = 0.75), which showed greater 
efficiency than that of 5-iodo (Φr = 0.54) and 5-chloro (Φr = 0.32) substitutions.  This 
series illustrates that there is an interplay between the heavy atom effect on spin-orbit 
coupling (SOC) and the effect of electron withdrawing substituents enhancing the 
reactivity of the N-centered radical towards the electron rich diene of the furan pendant.  
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Pauling electronegativities, atomic SOC values, and the quantum yield (Φr) of 
cycloaddition are compiled in Table 2.1 for this series.  Iodo substitution provides 
sufficient SOC but shows low electronegativity, while choloro substitution displays the 
inverse.  Bromine lies in the middle when it comes to SOC and electronegativity, which 
may explain the higher Φrs compared to the other compounds in the series. 
 
 Cl Br I 
Electronegativity 3.16 2.96 2.66 
Atomic SOC cm-1 587 2460 5069 
QY, cycloaddition 0.32 
(2.1d) 
0.75 
(2.1b) 
0.54 
(2.1c) 
 
Table 2.1 [Adopted From J. Phys. Chem. A
21
] 
 
The preceding body of evidence shows that the cycloaddition of o-azaxylylenes 
proceeds through a triplet state, eliminating pathways 1-3; however, this leaves two 
possible scenarios.  ESIPT could potentially occur in the singlet (Pathway 4) or triplet 
state (Pathway 5).  It has been established that ESIPT does not occur in the triplet state, 
as the two phosphorescence bands of the triplet 2-aminobenzophenone conformers, one 
being the EISPT species and the other being the ketone, decay independently of one 
another
22
 leaving pathway 4 as the only remaining excited state pathway.  To conclude, 
the mechanism proceeds through excitation to the singlet state, where ESIPT takes place, 
followed by ISC, radical addition of the N-centered radical resulting in a ground state 
species where the final radical recombination occurs yielding the cycloaddition products 
(Scheme 2.4). 
  34 
 
 
Scheme 2.4 
 
*The spectra and synthetic procedures for the materials presented in this Chapter 
are given in the experimental section of Chapter 3, as the materials used in this 
study are a subset of those synthesized in the following chapter. 
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Chapter 3: Postphotochemical Modifications  
 The mechanistic studies in the previous chapter have provided insight into the 
process of o-azaxylylene cycloaddition and allow those utilizing this chemistry to do so 
optimally.  Moving forward, the next topic to address would be whether these novel 
scaffolds are amenable to postphotochemical modifications to the overall topology and 
probe unexplored regions of chemical space.  The research in this chapter was published 
in the Journal of Organic Chemistry.
12
 
 
Introduction 
 Combinatorial chemistry and diversity oriented synthesis are valuable tools, as 
they are capable of producing large libraries of compounds efficiently.
9
  It has been 
shown that o-azaxylylene cycloadditions are capable of producing significantly diverse 
frameworks and adhere to the fundamentals of diversity oriented synthesis.
20
  Further 
modification of the scaffold can yield structures reminiscent of natural products, and 
expands the area of chemical space explored.
9
  According to an extensive study by 
Roughley and Jordan,
27
 Suzuki coupling accounts for 40% of all C-C bond forming 
reactions, and sp
2
-sp
2
 coupling is one of the most commonly used reactions by medicinal 
chemists in the pursuit of drug candidates. 
  
Suzuki coupling holds other advantages that 
serve as a good starting point for postphotochemical modification, in that there are many 
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boronic acids commercially available, and the procedures are well documented.  This 
study sets out to explore the modification of these cycloaddition adducts using Suzuki 
coupling.   
 
Results and Discussion 
 To incorporate Suzuki coupling into the synthesis of the cycloaddition scaffolds 
two coupling approaches were explored (Scheme 3.1): pre-photochemical coupling of the 
heteroboronic acid with the halogen-substituted photoprecursor (path a), and post-
photochemical coupling of the cycloaddition products (path b).  This was the first goal of 
the study, as extended conjugation could potentially affect the photoefficency.   
 
 
  
 
 
3
7
 
 
 
Scheme 3.1 [Adopted From J. Org. Chem
12
] 
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Synthesis of 3.1a was accomplished by acylating the 5-bromophenylmethanol 
with 2-furanpropanoyl chloride, and the product was then either subjected to Suzuki 
coupling followed by PCC oxidation, and irradiation (path a) or oxidized by PCC then 
irradiated and coupled to the aryl boronic acid (path b).  Both the halogen (3.3a), and 
hetroaryl (3.3b) photoprecursors were irradiated with a Rayonet broadband 300-400 nm 
UV source, and the optimal solvent for irradiation was determined to be 5% aqueous 
acetonitrile.  Irradiation of both photoprecursors yielded one diastereomer of the [4 + 2] 
(syn) and [4 + 4] (anti) cycloaddition products in an approximate ratio of 1:1, where syn 
and anti refer to the relative position of the bridged oxygen and the hydroxyl group.  
Suzuki coupling of the photoproducts resulted in some degradation of the [4 + 2] product.  
The yields were comparable for both pathway a and b, 44% and 35% respectively.  
However, the quantum efficiency differed considerably between photoprecursors 3.3a 
and 3.3b, being 3.7 times greater for the halogen substituted precursor (3.3a) utilized in 
pathway b, the reasoning being explained in Chapter 2.  Given the similar overall yields, 
it was decided to follow path b to probe the scope of the reaction due to the increased 
quantum efficiency. 
In keeping with the principles of DOS, a modular approach was implemented to 
gain access to a diverse array of photoprecursors.  Modifications to the halogen and its 
position in the aromatic ring, the linker connecting the 2-acylaniline to the furan pendant, 
and the substituent on the carbonyl were employed yielding the compounds seen in Table 
3.1.
  
 
 
3
9
 
o-Formyl- or 
o-acyl-aniline 
Linker 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
  
 Isolated yields of photoprecursors are given 
Table 3.1 [Adopted From J. Org. Chem
12
] 
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Photoprecursors 3.3a-e, 3.9, and 3.12-16 were synthesized according to Scheme 
3.2 and 3.3.  Halogen substituted alcohols 3.7a, c-e, 3.8 and ketones 3.10, 3.11 were 
acylated with furanpropanoyl chloride 3.6.  After acylation, ketones 3.12 and 3.13 were 
irradiated, while alcohols were oxidized using PCC to yield photoprecursors 3.3a, c-e.  
Halogen-substituted methyl anthranilates were coupled in the same fashion, reduced with 
LiAlH4, and oxidized using PCC. 
 
 
Scheme 3.2 [Adopted From J. Org. Chem
12
] 
 
 Diversification of the linker was achieved using a peptoid synthesis-inspired
28,29 
approach with bromoacetyl bromide (Scheme 3.3).  Bromoacylation of alcohol 3.7a or 
ketone 3.11 was followed by the addition of furfuryl or benzyl amine, and subsequent 
acylation with either pivaloyl or furoyl chloride, respectively.  The alcohol was then 
oxidized using PCC. 
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Scheme 3.3 [Adopted From J. Org. Chem
12
] 
 
 The products synthesized from photochemical cyclization and subsequent Suzuki 
coupling are presented in Scheme 3.4, and the yields can be found in Table 3.2.  In all 
cases irradiation produced both the [4 +2] in [4 + 4] cycloaddition products with good 
diastereoselectivity, and on average the irradiations were complete in less than 5 hours.  
The mixture of cycloaddition products were subjected to Suzuki coupling to yield the 
fused biaryls and purified by column chromatography.  Palladium-catalyzed cross 
coupling proved to be sensitive to the addition of heteroatoms in the linker, as 
demonstrated in two of the three cases where the peptoid-inspired methodology was 
employed.  In these instances, Suzuki coupling resulted in the complete degradation of [4  
+ 2] cycloaddition products bringing the yield below 40%.
  
 
 
 
 
 
 
 
 
4
2
 
 
Scheme 3.4 [Adopted From J. Org. Chem
12
]
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Photoprecursor Photoproducts 
ratio [4+2]:[4+4]
a
 
Suzuki coupling 
product from [4+2]
b
 
Suzuki coupling 
product from 
[4+4]
b
 
3.3a 3.4a:3.5a = 1:1 
 
3.4f, 30% 3.5f, 44% 
3.4b, 7% 3.5b, 28% 
3.3d 
 
3.4d:3.5d = 1:1 3.4g, 17% 3.5g, 26%
c 
3.4h, 27% 3.5h, 39% 
3.9 3.17a:3.18a = 1:0.8 3.17b, 30% 3.18b, 24% 
3.12 3.19a:3.20a = 1:1.1 3.19b, 28% 3.20b, 30% 
3.13 3.21a:3.22a = 1:1.9 3.21b, 36% 3.22b, 16% 
3.14 3.23a:3.24a = 1:1.4 3.23b 19% 3.24b, 12% 
3.15 3.25a:3.26a = 1:1.5 3.25b, -- 3.26b, 20% 
3.16 3.27a:3.28a = 1:16 3.27b, -- 3.28b, 36% 
a
Determined by NMR of the reaction mixture after completion of irradiation.  For [4 + 4] the 
double bond proton at approximately 6.4 ppm (dd, J = 6.0, 2.0 Hz, 1H), and for [4 + 2] the 
double bond proton at approximately 6.3 ppm (t, 2.8 Hz, 1H); 
b
isolated yields; 
c
the primary [4+4] 
photoproduct rearranges from the bicyclo[4.2.1] to bicyclo[3.3.1] framework. 
 
Table 3.2 [Adopted From J. Org. Chem
12
] 
 
 Coupling conditions were dependent on the boronic acid being used.  The catalyst 
of choice for coupling with 3-pyridine boronic acid was Pd2(dba)3 (0.9 mol %) using 
PCy3 as a ligand, while 2-furyl and 2-thienyl boronic acids were coupled with 
Pd(PPh3)4 (5 mol %).  Bromine substituted substrates were reactive with 3-pyridine 
boronic acids; however, thienyl and furyl boronic acids required iodine substituted 
substrates.  All attempts using MIDA
30
 boronates failed.  X-Ray analysis was performed 
on crystalline products unambiguously proving their structure and stereochemistry (see 
experimental).   
Additionally, a rearrangement from the bicyclo [4.2.1] to a bicyclo [3.3.1] skeletal 
structure was observed when 3.5g was subjected to silica during chromatography 
(Scheme 3.5), which results from ring opening and closure of the [4 + 4] photo product.  
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It was found that heating the [4 + 4] cycloaddition in DMSO also produces the [3.3.1] 
rearrangement product. 
 
 
Scheme 3.5 [Adopted From J. Org. Chem
12
] 
 
Since this research was published back in 2014, other novel post photochemical 
modifications have been implemented demonstrating the synthetic utility of these 
cycloaddition products.  For example, Umstead et al. illustrated that the alkene generated 
from photochemical cycloaddition was reactive to 1,3-dipoles, and N-phenyl-aryl-2-
ylmethanimines
15
 (Scheme 3.6), yielding an array of products with significantly diverse 
core scaffolds.   
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Scheme 3.6 
  
Given the growing body of data regarding the synthetic utility of photogenerated 
o-azaxylylenes it is clear that this methodology of producing fused ring systems is 
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aligned with the principles of DOS.  These reactions show a high degree of 
diastereoselectivity, produce unprecedented fused ring systems, and are amenable to 
postphotochemical modifications. 
 
Experimental 
Common solvents were purchased from Pharmco and used as is, except for THF, 
which was refluxed over and distilled from potassium benzophenone ketyl prior to use. 
Common reagents were purchased from Aldrich or TCI America and used without 
additional purification, unless indicated otherwise. NMR spectra were recorded at 25
°
C 
on a Bruker Avance III 500 MHz in CDCl3 with TMS as an internal standard (unless 
noted otherwise) High resolution mass spectra were obtained on the MDS SCIEX/Applied 
Biosystems API QSTARTM Pulsar i Hybrid LC/MS/MS System mass spectrometer by Dr. 
Shuji Kato and Dr. Dan Gu at the University of Colorado at Boulder.  Flash column 
chromatography was performed using Teledyne Ultra Pure Silica Gel (230 – 400 mesh) 
on a Teledyne Isco Combiflash Rf using Hexanes/EtOAc or DCM/Methanol as an eluent. 
        
2-Furanpropanoyl chloride
31
 (3.6): To a stirred solution of 3-(2-
furyl)propanoic acid (1 eq, 1.15 g, 8.2 mmol) in 15 mL of DCM was 
added SOCl2 (1.3 eq, 0.79 mL, 11 mmol).  The solution was refluxed for 4 hours, allowed 
to cool to room temperature, and concentrated, yielding 1.28 g (99%) of the product.  
1
H 
NMR (500 MHz, CDCl3) δ 7.35 (dd, J = 1.9, 0.9 Hz, 1H), 6.32 (dd, J = 3.2, 1.9 Hz, 1H), 
6.10 (m, 1H), 3.27 (t, J = 7.3 Hz, 2H), 3.07 (t, J = 7.3 Hz, 2H).  
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Synthesis of halogen-substituted o-hydroxymethylanilines and o-acetylanilines 
 
Methyl 2-amino-4-bromobenzoate
32 
(S1): To an ice cooled solution 
of 4-bromo-2-nitrobenzoic acid (1.50 g,  6.10 mmol) in DMF (15 
mL) was added DBU (8.3 mL, 55 mmol), followed by the addition of 
MeI (3.4 mL, 54.9 mmol).  The reaction was allowed to stir overnight, poured into water 
(30 mL), extracted with EtOAc (4 x 75 mL), dried over Na2SO4, filtered and concentrated 
yielding 1.54 g (97%) of methyl 4-bromo-2-nitrobenzoate.  
1
H NMR (500 MHz, 
CDCl3) δ 8.03 (d, J = 1.9 Hz, 1H), 7.83 (dd, J = 8.2, 1.9 Hz, 1H), 7.67 (d, J = 8.2 Hz, 
1H), 3.93 (s, 3H). To a solution of methyl 4-bromo-2-nitrobenzoate (1.52 g, 5.85 
mmol) in a 1:1 mixture of EtOAc and DCM (12 mL) was added SnCl2∙2H2O (6.18 g, 
27.4 mmol).  After 24 hours the mixture was concentrated, diluted with a solution of sat. 
aq. NaHCO3, extracted with DCM, and concentrated yielding 1.15g (82%) of the title 
compound over two steps.  
1
H NMR (500 MHz, CDCl3) δ 7.72 (d, J = 8.6 Hz, 1H), 6.87 
(d, J = 1.9 Hz, 1H), 6.78 (dd, J = 8.6, 1.9 Hz, 1H), 5.81 (s, 2H), 3.88 (s, 3H). 
 13
C NMR 
(126 MHz, CDCl3) δ 168.1, 151.2, 132.6, 128.7, 119.5, 119.0, 109.6, 51.7. 
      
2-Amino-5-bromobenzyl alcohol
33
 (S2):  Methyl 2-amino-5-
bromobenzoate (3.00 g, 13.0 mmol) in THF (9 mL) under nitrogen 
atmosphere was cooled to -41 °C using a acetonitrile/CO2 (s) cooling 
bath, and DIBAL-H (39.1 mL of a 1.0 M solution in hexanes, 43.0 mmol) was slowly 
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added to the stirred solution.  After maintaining at -41 °C for 1.5 hours, the solution was 
allowed to reach room temperature and left to stir overnight.  The solution was cooled in 
an ice water bath, quenched by the addition of methanol, a solution of sat. aq. sodium 
potassium tartrate was added, and the mixture was allowed to stir for 30 min.  The 
organic phase was extracted with Et2O (3 x 100 mL), and concentrated yielding 2.41 g 
(92%) of the product.  
1
H NMR (500 MHz, CDCl3) δ 7.24 (m, 2H), 6.61 (d, J = 8.3 Hz, 
1H), 4.66 (d, J = 4.5 Hz, 2H), 4.22 (s, 2H). 
   
4-Bromo-2-((trimethylsilyl)methyl)aniline (S3):  
Chlorotrimethylsilane (1.16 mL, 9.14 mmol) was added to a stirred 
solution of 2-amino-5-bromobenzyl alcohol (1.68 g, 8.33 mmol) 
and triethylamine (2.32 mL, 16.6 mmol) in DCM (70 mL). The reaction mixture was 
stirred at room temperature overnight.  The mixture was quenched with a solution of sat. 
aq. NH4Cl (50 mL), the organic layer was separated, and the aqueous phase was extracted 
with DCM (3 x 100 mL).  The organic fractions were combined, dried over Na2SO4, 
filtered, and concentrated yielding 2.35 g (94%) of the product.  
1
H NMR (500 MHz, 
CDCl3) δ 7.19 (m, 2H), 6.57 (d, J = 8.2 Hz, 1H), 4.61 (s, 2H), 4.18 (s, 2H), 0.16 (s, 9H). 
 
2-Amino-4-bromobenzyl alcohol
34
 (S4): Methyl 2-amino-4-
bromobenzoate (1.14 g, 4.95 mmol) in THF (5.5 mL) under nitrogen 
atmosphere was cooled to -41 °C.  DIBAL-H (16.35 mL of a 1.0 M 
solution in hexanes, 16.35 mmol) was slowly added to the stirred solution.  After 
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remaining at -41 °C for 1.5 hours, the solution was allowed to reach room temperature 
and left to stir overnight.  The solution was cooled in an ice water bath, quenched by the 
addition of methanol (35 mL), a solution of sat. aq. sodium potassium tartrate was added 
(70 mL), and the mixture was allowed to stir for 6 hours.  The organic phase was 
extracted with Et2O (3 x 125 mL), and concentrated yielding 0.98 g of (2-amino-4-
bromophenyl)methanol which was used without further purification.  
1
H NMR (500 
MHz, CDCl3) δ 6.95 (d, J = 7.9 Hz, 1H), 6.88 (d, J = 1.9 Hz, 1H), 6.85 (dd, J = 7.9, 1.9 
Hz, 1H), 4.66 (d, J = 5.1 Hz, 2H), 4.29 (s, 2H), 1.54 (m, 1H).   
 
5-Bromo-2-((trimethylsilyloxy)methyl)aniline (S5): 
Chlorotrimethylsilane (0.69 mL, 5.4 mmol) was added to a stirred 
solution of (2-amino-4-bromophenyl)methanol (0.98 g 4.9 mmol) and triethylamine 
(1.36 mL, 9.75 mmol) in DCM (43 mL). The reaction mixture was stirred at room 
temperature overnight.  The mixture was quenched with a solution of sat. aq. NH4Cl (70 
mL), the organic layer was separated, and the aqueous phase was extracted with DCM (3 
x 100 mL).  The organic fractions were combined, dried over Na2SO4, filtered, and 
concentrated yielding 1.11 g of 5-bromo-2-((trimethylsilyloxy)methyl)aniline which was 
used without further purification. 
 1
H NMR (500 MHz, CDCl3) δ 6.90 (d, J = 7.8 Hz, 1H), 
6.84 (d, J = 1.8 Hz, 1H), 6.82 (dd, J = 7.8, 1.9 Hz, 1H), 4.61 (s, 2H), 4.26 (s, 2H), 0.14 (s, 
9H).   
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2-Amino-5-iodobenzyl alcohol
35
 (S6): Methyl 5-iodoanthranilate 
(3.00 g, 10.8 mmol) in THF (7.5 mL) under nitrogen atmosphere was 
cooled to -41 °C.  DIBAL-H (32.7 mL of a 1.1 M solution in 
cyclohexane, 36 mmol) was slowly added to the stirred solution.  After remaining at -41 
°C for 1.5 hours, the solution was allowed to reach room temperature and left to stir 
overnight.  The solution was cooled in an ice water bath, quenched by the addition of 
methanol, a solution of sat. aq. sodium potassium tartrate was added, and the mixture was 
allowed to stir for 30 min.  The organic phase was extracted with Et2O (3 x 100 mL), and 
concentrated yielding 2.48 g (92%) of the product.  
1
H NMR (500 MHz, CDCl3) δ 7.41 
(dd, J = 8.3, 2.2 Hz, 1H), 7.39 (d, J = 2.1 Hz, 1H), 6.51 (d, J = 8.3 Hz, 1H), 4.64 (d, J = 
5.3 Hz, 2H), 4.24 (s, 2H).   
 
4-Iodo-2-((trimethylsilyloxy)methyl)aniline (S7): 
Chlorotrimethylsilane (0.49 mL, 3.8 mmol) was added to a stirred 
solution of 2-amino-5-iodobenzyl alcohol (0.87 g, 3.5 mmol) and 
triethylamine (0.98 mL, 7.0 mmol) in DCM (32 mL). The reaction mixture was stirred at 
room temperature overnight.  The mixture was quenched with a solution of sat. aq. 
NH4Cl (50 mL), the organic layer was separated, and the aqueous phase was extracted 
with DCM (3 x 100 mL).  The organic fractions were combined, dried over Na2SO4, 
filtered, and concentrated yielding 0.94 g (83%) of the product.
 1
H NMR (500 MHz, 
CDCl3) δ 7.37 (dd, J = 8.2, 2.2 Hz, 1H), 7.35 (d, J = 2.1 Hz, 1H), 6.47 (d, J = 8.3 Hz, 
1H), 4.59 (s, 2H), 4.21 (s, 2H), 0.15 (s, 9H). 
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1-(2-amino-5-bromophenyl)ethanone
36
 (3.7):   2’-
Aminoacetophenone (10 g, 73.96 mmol) was dissolved in Ac2O, stirred 
for 2 hours and concentrated.  The residue was then dissolved in DCM, 
treated with Br2 (6 mL), allowed to stir for 3 hours, quenched with water, filtered, and the 
collected solid was washed with water.  The solid residue was transferred to a round 
bottomed flask, dissolved in 2 M HCl (200 mL), and the solution was heated at 90 °C for 
4 hours.  The solution was allowed to reach room temperature, basified to pH 12, 
extracted with EtOAc (3 x 50 mL), dried over Na2SO4, and concentrated yielding 13.5 g 
(85%) of the product.  
1
H NMR (500 MHz, CDCl3) δ 7.82 (s, 1H), 7.35 (d, J = 8.8 Hz, 
1H), 6.58 (d, J = 8.8, 0.9 Hz, 1H), 6.32 (s, 2H), 2.58 (s, 3H).  
13
C NMR (126 MHz, 
CDCl3) δ 199.6, 149.1, 137.0, 134.1, 119.4, 119.0, 106.6, 27.8. 
  
N-(4-bromo-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide
37
 (S8):  
5,6,7,8-Tetrahydro-1- naphthylamine (3.0 mL, 21.6 mmol) in EtOH (10 
mL) was added dropwise to an ice-cooled solution of acetic anhydride 
(4.08 mL, 43.2 mmol) in EtOH (40 mL). The mixture was stirred for 16 
hours at room temperature. Subsequently, the solvent was removed under reduced 
pressure to yield N-(5,6,7,8- tetrahydro-1-naphthyl)-acetamide as a white solid which 
was used without further purification 
1
H NMR (500 MHz, CDCl3) δ = 7.63 (d, J=7.9, 
1H), 7.15 (t, J=7.8, 1H), 6.95 (d, J=7.5, 1H), 6.89 (s, 1H), 2.81 (m, 2H), 2.62 (m, 2H), 
2.23 (s, 3H), 1.87 (m, 2H), 1.80 (m, 2H).  To a cooled solution of N-(5,6,7,8- 
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tetrahydro-1-naphthyl)-acetamide in AcOH (55 mL) was slowly added a solution of 
Br2 (3.36 mL, 65.2 mmol) in AcOH (4 mL) so that the temperature remained below 17 
°C.  The reaction mixture was then allowed to stir at room temperature for 24 hours.  The 
mixture was poured over ice water, the resulting suspension was filtered, and the 
collected solid was washed with water.  The solid was dissolved in DCM (200 mL) and 
H2O (50 mL), the organic phase was separated, and the aqueous phase was extracted with 
DCM (3 x 100 mL).  The organic phases were combined, dried over Na2SO4, filtered, and 
concentrated yielding 6.98 g (99.6%) of the product.  
1
H NMR (500 MHz, CDCl3) δ 7.53 
(d, J = 8.6 Hz, 1H), 7.43 (d, J = 8.6 Hz, 1H), 6.89 (s, 1H), 2.77 (m, 2H), 2.61 (m, 2H), 
2.24 (s, 3H), 1.81 (m, 4H).   
 
N-(4-Bromo-8-oxo-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide (S9):  
N-(4-bromo-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide (3.09 g, 11.5 
mmol) in acetone (80 mL) and 15% aqueous MgSO4 (1.90 g, 15.8 mmol 
in 11 mL of H2O) was treated with KMnO4 (5.47 g, 34.6 mmol) in 
portions.  The mixture was allowed to stir for 12 hours, filtered through Celite®, and the 
solids were washed with CHCl3 (100 mL) and H2O (100 mL).  The aqueous layer was 
extracted with CHCl3 (4 x 100 mL).  The organic fractions were combined, washed with 
brine, and dried over Na2SO4, and concentrated yielding 1.90 g (58.6%) of the desired 
product.  
1
H NMR (500 MHz, CDCl3) δ 12.16 (s, 1H), 8.58 (d, J = 9.1 Hz, 1H), 7.72 (d, J 
= 9.1 Hz, 1H), 3.06 (t, J = 6.2 Hz, 2H), 2.72 (m, 2H), 2.25 (s, 3H), 2.14 (m, 2H). 
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8-Amino-5-bromo-3,4-dihydronaphthalen-1(2H)-one (3.8):  A stirred 
solution of N-(4-bromo-8-oxo-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide 
(1.90 g, 6.74 mmol) in 6M HCl (100 mL) was heated at 90 °C for 8 hours. 
The mixture was cooled to room temperature and the volatiles were removed under 
vacuum. Ice was added to the mixture, followed by 2M NaOH until pH of 8 was reached. 
The aqueous layer was extracted with EtOAc, the organic fractions were combined, 
washed with brine, dried, filtered, and the concentrated to give 1.26 g of the product 
(77.9%).  
1
H NMR (500 MHz, CDCl3) δ 7.39 (d, J = 8.9 Hz, 1H), 6.55 (s, 2H), 6.43 (d, J 
= 8.8 Hz, 1H), 2.96 (t, J = 6.2 Hz, 2H), 2.65 (m, 2H), 2.08 (m, 2H). 
 
Photoprecursors synthesis 
 
 
General procedure for the reaction of 2-furanpropanoyl chloride with 
amines (FC): A crude solution of 2-furanpropanoyl chloride (1.2 -1.5 eq) in dry THF 
(25 mL) was added dropwise to an ice-cooled stirred solution of substituted anilines (1 
eq) and anhydrous pyridine (1.1 eq) in THF (50 mL).  The solution was allowed to reach 
room temperature and left to stir overnight.  The reaction mixture was then diluted with 
water (100 mL), extracted with EtOAc (4 x100 mL), the combined organic fractions were 
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washed with 10% NaOH (100 mL), dried over Na2SO4, filtered, and concentrated. The 
product was purified when necessary using flash chromatography. 
 
General procedure for the synthesis of and N-(2-acetylphenyl)-2-
bromoacetamides (BB): Bromoacetyl bromide (1.1 eq) in dry DCM (10 mL) was slowly 
added to a stirred solution of amine (1 eq), pyridine (1.1 eq) in dry DCM (20 mL) at 0
o
C 
under nitrogen atmosphere. The reaction mixture was left stirring overnight, then it was 
quenched with water (10 mL) and the aqueous phase was extracted with DCM (2x75 
mL).  Combined organic layers were dried over Na2SO4 and concentrated, giving the 
crude product, which was used further without purification. 
 
N-(4-chloro-2-formylphenyl)-3-(furan-2-
yl)propanamide (3.3c): General procedure FC was 
followed using 2-furanpropanoyl chloride (6) (0.51 g, 3.2 
mmol, 1 eq), 2-amino-5-chlorobenzyl alcohol (0.50 g, 3.2 mmol, 1 eq) and anhydrous 
pyridine (0.28 mL, 3.5 mmol) in THF (10 mL). The workup and purification by flash 
chromatography yielded 0.67 g (2.4 mmol, 75%) of N-(4-chloro-2-
(hydroxymethyl)phenyl)-3-(furan-2-yl)propanamide. 
1
H NMR (500 MHz, CDCl3) δ 
8.45 (s, 1H), 8.03 (d, J = 8.7 Hz, 1H), 7.36 (m, 1H), 7.31 (dd, J = 8.7, 2.4 Hz, 1H), 7.20 
(d, J = 2.4 Hz, 1H), 6.32 (t, J = 2.4 Hz, 1H), 6.11 (d, J = 3.2 Hz, 1H), 4.62 (d, J = 4.5 Hz, 
2H), 3.11 (t, J = 7.4 Hz, 2H), 2.77 (t, J = 7.4 Hz, 2H), 2.07 (s, 1H). To a stirred solution 
of N-(4-chloro-2-(hydroxymethyl)phenyl)-3-(furan-2-yl)propanamide (0.67 g, 2.4 
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mmol) in dry DCM (100 mL) was added PCC (0.78 g, 3.6 mmol). The reaction mixture 
was left stirring overnight, filtered through a layer of silica gel, and evaporated yielding 
0.64 g (2.3 mmol, 54% over two steps) of the title compound. 
1
H NMR (500 MHz, 
CDCl3) δ 11.08 (s, 1H), 9.88 (d, J = 0.7 Hz, 1H), 8.77 (d, J = 9.0 Hz, 1H), 7.66 (d, J = 2.5 
Hz, 1H), 7.58 (dd, J = 9.1, 2.5 Hz, 1H), 7.34 (dd, J = 1.9, 0.9 Hz, 1H), 6.30 (dd, J = 3.2, 
1.9 Hz, 1H), 6.09 (m, 1H), 3.11 (m, 2H), 2.84 (m, 2H).  
13
C NMR (126 MHz, CDCl3) δ 
194.3, 171.2, 153.8, 141.3, 139.3, 136.0, 135.0, 128.0, 122.5, 121.6, 110.2, 105.6, 36.5, 
23.6.   
 
Methyl 5-bromo-2-(3-(furan-2-yl)propanamido)benzoate 
(S10): General procedure FC was followed using  2-
furanpropanoyl chloride (1.2 eq, 1.67 g, 10.5 mmol), methyl 
2-amino-5-bromobenzoate (1 eq, 2.00 g, 8.6 mmol) and 
anhydrous pyridine (1.1 eq, 0.76mL, 9.5mmol).  The workup yielded 3.00 g (99%) of the 
product. 
1H NMR (500 MHz, CDCl3) δ 11.05 (s, 1H), 8.68 (d, J = 9.1 Hz, 1H), 8.17 (d, J 
= 2.5 Hz, 1H), 7.65 (dd, J = 9.1, 2.5 Hz, 1H), 7.33 (dd, J = 1.9, 0.8 Hz, 1H), 6.29 (dd, J = 
3.2, 1.9 Hz, 1H), 6.09 (m, 1H), 3.96 (s, 3H), 3.11 (m, 2H), 2.81 (m, 2H). 
13
C NMR (126 
MHz, CDCl3) δ 170.7, 167.6, 154.0, 141.3, 140.5, 137.4, 133.3, 122.1, 116.4, 114.8, 
110.2, 105.5, 52.7, 36.7, 23.7. 
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N-(4-Bromo-2-formylphenyl)-3-(furan-2-yl)propanamide 
(3.3a): To a suspension of LiAlH4 (0.88 g, 23 mmol) in THF 
(12 mL) at -78 °C under nitrogen atmosphere was added 
methyl 5-bromo-2-(3-(furan-2-yl)propanamido)benzoate (4.29 g, 12.2 mmol) 
dissolved in THF (24 mL).  The mixture was allowed to stir overnight, treated with water 
(1 mL), 10% NaOH (1 mL), followed by an additional allotment of water (3 mL), and 
dried over Na2SO4.  The solvent was filtered and concentrated yielding 3.52 g of N-(4-
bromo-2-(hydroxymethyl)phenyl)-3-(furan-2-yl)propanamide which was used 
without further purification. 
1
H NMR (500 MHz, CDCl3) δ 8.50 (s, 1H), 7.98 (d, J = 8.7 
Hz, 1H), 7.45 (dd, J = 8.7, 2.4 Hz, 1H), 7.35 (m, 2H), 6.32 (dd, J = 3.1, 1.9 Hz, 1H), 6.11 
(m, 1H), 4.61 (s, 2H), 3.10 (t, J = 7.4 Hz, 2H), 2.76 (t, J = 7.4 Hz, 2H), 2.21 (s, 1H).  
13
C 
NMR (126 MHz, CDCl3) δ 170.4, 154.0, 141.3, 136.4, 131.9, 131.5, 131.4, 124.2, 116.9, 
110.4, 105.8, 63.8, 36.2, 24.0.  To the alcohol (3.52 g) in dry DCM (250 mL) was added 
PCC (2.63 g, 12.2 mmol). The reaction mixture was left stirring overnight, filtered 
through a layer of silica gel, and evaporated yielding 2.11 g (53%) of the product over 
two steps.
  1
H NMR (500 MHz, CDCl3) δ 11.08 (s, 1H), 9.87 (s, 1H), 8.72 (d, J = 8.9 Hz, 
1H), 7.80 (d, J = 2.4 Hz, 1H), 7.72 (dd, J = 9.0, 2.4 Hz, 1H), 7.34 (dd, J = 1.9, 0.9 Hz, 
1H), 6.30 (dd, J = 3.2, 1.9 Hz, 1H), 6.09 (m, 1H), 3.11 (m, 2H), 2.84 (m, 2H).
  13
C NMR 
(126 MHz, CDCl3) δ 194.2, 171.2, 153.8, 141.3, 139.8, 138.9, 138.0, 122.9, 121.9, 115.0, 
110.2, 105.6, 36.5, 23.6. HRMS (ESI) calcd for C14H13BrNO3
+
 (MH
+
) 322.0073, found 
322.0067. 
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N-(5-bromo-2-formylphenyl)-3-(furan-2-
yl)propanamide (3.9):  General procedure FC was 
followed using 2-furanpropanoyl chloride (0.90 g, 5.7 
mmol), 5-bromo-2-((trimethylsilyloxy)methyl)aniline (1.11 g, 4.05 mmol) and 
anhydrous pyridine (0.49 mL, 6.1 mmol).  Upon workup 1.27 g of N-(5-bromo-2-
(hydroxymethyl)phenyl)-3-(furan-2-yl)propanamide was isolated, which was used 
without further purification.  
1
H NMR (500 MHz, CDCl3) δ 8.68 (s, 1H), 8.31 (d, J = 1.2 
Hz, 1H), 7.35 (dd, J = 1.9, 0.9 Hz, 1H), 7.20 (dd, J = 8.1, 2.2 Hz, 1H), 7.02 (d, J = 8.1 
Hz, 1H), 6.32 (dd, J = 3.2, 1.9 Hz, 1H), 6.10 (m, 1H), 4.60 (s, 2H), 3.08 (m, 2H), 2.75 
(m, 2H).  To N-(5-bromo-2-(hydroxymethyl)phenyl)-3-(furan-2-yl)propanamide 
(1.27 g, 3.71 mmol) in DCM (90 mL) was added PCC (4.80 g, 22.3 mmol).  The reaction 
mixture was left stirring for 12 h, filtered through a layer of silica gel using EtOAc, 
concentrated, and the mixture was subjected to flash chromatography yielding 0.40 g 
(24%) of the product over four steps.  
1
H NMR (500 MHz, CDCl3) δ 11.22 (s, 1H), 9.89 
(s, 1H), 9.05 (d, 1H), 7.53 (d, J = 8.2 Hz, 1H), 7.39 (dd, J = 8.2, 1.8 Hz, 1H), 7.34 (dd, J 
= 1.9, 0.9 Hz, 1H), 6.30 (dd, J = 3.2, 1.9 Hz, 1H), 6.10 (m, 1H), 3.11 (m, 2H), 2.84 (m, 
2H).  
13
C NMR (126 MHz, CDCl3) δ 194.6, 171.3, 153.8, 141.4, 141.3, 136.8, 131.9, 
126.3, 123.0, 120.2, 110.2, 105.6, 36.4, 23.5.  HRMS (ESI) calcd for C14H13BrNO3
+
 
(MH
+
) 322.0073, found 322.0080. 
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N-(2-Formyl-4-iodophenyl)-3-(furan-2-yl)propanamide 
(3.3d):  General procedure FC was followed using 2-
furanpropanoyl chloride (0.79 g, 5.0 mmol), 4-iodo-2-
((trimethylsilyloxy)methyl)aniline (0.94 g, 2.9 mmol) and dry 
pyridine (0.40 mL, 5.0 mmol) in THF (10 mL).  Upon workup 0.90 g of N-(4-iodo-2-
(hydroxymethyl)phenyl)-3-(furan-2-yl)propanamide  was isolated which was used 
without further purification.  
1H NMR (500 MHz, CDCl3) δ 8.50 (s, 1H), 7.89 (d, J = 8.5 
Hz, 1H), 7.65 (dd, J = 8.6, 2.1 Hz, 1H), 7.53 (d, J = 2.2 Hz, 1H), 7.36 (dd, J = 1.9, 0.9 Hz, 
1H), 6.32 (dd, J = 3.2, 1.9 Hz, 1H), 6.10 (m, 1H), 4.60 (d, J = 5.7 Hz, 2H), 3.10 (t, J = 7.4 
Hz, 2H), 2.76 (t, J = 7.4 Hz, 2H), 2.10 (s, 1H).  To N-(4-iodo-2-
(hydroxymethyl)phenyl)-3-(furan-2-yl)propanamide  (0.90 g) in DCM (60 mL) was 
added PCC (3.15 g, 14.6 mmol).  The reaction mixture was left stirring for 8 hours, 
filtered through a layer of silica gel using EtOAc, concentrated, and the mixture was 
subjected to flash chromatography yielding 0.37 g (34%) of the product over two steps.  
1
H NMR (500 MHz, CDCl3) δ 11.08 (s, 1H), 9.85 (s, 1H), 8.58 (d, J = 8.9 Hz, 1H), 7.97 
(d, J = 2.2 Hz, 1H), 7.89 (dd, J = 8.9, 2.2 Hz, 1H), 7.33 (dd, J = 1.8, 0.9 Hz, 1H), 6.29 
(dd, J = 3.2, 1.9 Hz, 1H), 6.09 (m, 1H), 3.11 (m, 2H), 2.83 (m, 2H).
  13
C NMR (126 MHz, 
CDCl3) δ 194.2, 171.2, 153.8, 144.6, 144.1, 141.4, 140.4, 123.3, 122.0, 110.2, 105.6, 
84.7, 36.6, 23.6. HRMS (ESI) calcd for C14H13INO3
+
 (MH
+
) 369.9935, found 369.9945. 
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N-(2-acetyl-4-bromophenyl)-3-(furan-2-yl)propanamide 
(3.12): General procedure FC was followed using  2-
furanpropanoyl chloride (2 eq, 0.72 g, 2.8 mmol), 1-(2-amino-
5-bromophenyl)ethanone (1 eq, 0.30 g, 1.4 mmol) and 
anhydrous pyridine (1.5 eq, 0.17 mL, 2.1 mmol).  The concentration yielded 0.45 g 
(93%) of the product. 
 1
H NMR (500 MHz, CDCl3) δ 11.66 (s, 1H), 8.73 (d, J = 9.0 Hz, 
1H), 8.01 (d, J = 2.4 Hz, 1H), 7.66 (dd, J = 9.1, 2.4 Hz, 1H), 7.33 (dd, J = 1.9, 0.8 Hz, 
1H), 6.29 (dd, J = 3.2, 1.9 Hz, 1H), 6.08 (m, 1H), 3.10 (m, 2H), 2.81 (m, 2H), 2.68 (s, 
3H). 
 13
C NMR (126 MHz, CDCl3) δ 201.6, 171.1, 154.0, 141.3, 139.9, 137.8, 134.0, 
123.2, 122.6, 114.6, 110.2, 105.5, 36.7, 28.6, 23.7.  HRMS (ESI) calcd for C15H15BrNO3
+
 
(MH
+
) 336.0230, found 336.0235. 
 
N-(4-bromo-8-oxo-5,6,7,8-tetrahydronaphthalen-1-yl)-3-
(furan-2-yl)propanamide (3.13):  General procedure FC was 
followed using 2-furanpropanoyl chloride (3.8 mmol), 8-
amino-5-bromo-3,4-dihydronaphthalen-1(2H)-one (0.48 g, 
2.0 mmol) and dry pyridine (0.18 mL, 2.2 mmol). Purification by flash chromatography 
yielded 0.38 g of the title compound (50%). 
1
H NMR (500 MHz, CDCl3) δ 12.23 (s, 1H), 
8.61 (d, J = 9.1 Hz, 1H), 7.72 (d, J = 9.1 Hz, 1H), 7.33 (dd, J = 1.9, 0.8 Hz, 1H), 6.29 
(dd, J = 3.2, 1.9 Hz, 1H), 6.08 (m, 1H), 3.10 (m, 2H), 3.06 (t, J = 6.2 Hz, 2H), 2.82 (m, 
2H), 2.72 (m, 2H), 2.14 (m, 2H). 
 13
C NMR (126 MHz, CDCl3) δ 203.0, 171.2, 154.1, 
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144.1, 141.3, 141.3, 138.8, 120.0, 119.7, 117.5, 110.2, 105.4, 40.1, 36.8, 31.4, 23.7, 21.7.  
HRMS (ESI) calcd for C17H17BrNO3
+
 (MH
+
) 362.0386, found 362.0382. 
 
N-(2-(4-bromo-2-formylphenylamino)-2-oxoethyl)-N-
(furan-2-ylmethyl)pivalamide (S11):  General procedure BB 
was followed using  4-bromo-2-
((trimethylsilyl)methyl)aniline (2.28 g, 8.32 mmol), DIPEA 
(1.65 mL, 9.98 mmol) and bromoacetyl bromide (0.86 mL, 9.9 mmol).  The workup 
yielded 2-bromo-N-(4-bromo-2-(hydroxymethyl)phenyl)acetamide (3.07 g) which 
was used without further purification.  
1
H NMR (500 MHz, CDCl3) δ 9.51 (s, 1H), 8.02 
(d, J = 8.7 Hz, 1H), 7.50 (dd, J = 8.7, 2.4 Hz, 1H), 7.39 (d, J = 2.3 Hz, 1H), 4.75 (s, 2H), 
4.06 (s, 2H).  To N-(4-bromo-2-(hydroxymethyl)phenyl)acetamide (1.20 g) and 
DIPEA (0.71 mL, 4.1 mmol) in DCM (30 mL) was added furfuryl amine (0.49 mL, 5.5 
mmol).  The mixture was allowed to stir overnight, quenched with water (100 mL), the 
organic phase was separated, and the aqueous layer was extracted with DCM (3 x 100 
mL).  The combined organic fractions were washed with brine, dried over Na2SO4, 
filtered, and concentrated yielding N-(4-bromo-2-(hydroxymethyl)phenyl)-2-(furan-2-
ylmethylamino)acetamide (1.53 g crude) which was used without further purification.  
1
H NMR (500 MHz, CDCl3) δ 10.07 (s, 1H), 8.02 (d, J = 8.6 Hz, 1H), 7.45 (dd, J = 8.6, 
2.4 Hz, 1H), 7.41 (d, J = 2.4 Hz, 1H), 7.39 (dd, J = 1.9, 0.8 Hz, 1H), 6.36 – 6.34 (m, 1H), 
6.28 – 6.27 (m, 1H), 4.66 (s, 2H), 3.88 (s, 2H), 3.47 (s, 2H).  To N-(4-bromo-2-
(hydroxymethyl)phenyl)-2-(furan-2-ylmethylamino)acetamide (1.08 g) and DIPEA 
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(0.30 mL, 1.8 mmol) in DCM (100 mL) was added pivaloyl chloride (0.19 mL, 1.5 
mmol).  The mixture was allowed to stir overnight, quenched with water (100 mL), the 
organic phase was separated, and the aqueous layer was extracted with DCM (3 x 100 
mL).  The combined organic fractions were dried over Na2SO4, filtered, and 
concentrated.  Purification by flash chromatography yielded 0.40 g (29%) of the product 
over three steps.  
1H NMR (500 MHz, CDCl3) δ 9.11 (s, 1H), 7.88 (d, J = 8.7 Hz, 1H), 
7.39 (dd, J = 8.7, 2.4 Hz, 1H), 7.37 (dd, J = 1.8, 0.8 Hz, 1H), 7.32 (d, J = 2.4 Hz, 1H), 
6.36 (dd, J = 3.2, 1.9 Hz, 1H), 6.32 (m, 1H), 4.79 (s, 2H), 4.60 (d, J = 4.8 Hz, 2H), 4.10 
(s, 2H), 3.48 (s, 1H), 1.39 (s, 9H ). 
 
N-(2-(4-bromo-2-formylphenylamino)-2-oxoethyl)-N-(furan-
2-ylmethyl)pivalamide (3.14):  To a stirred solution of  N-(2-
(4-bromo-2-formylphenylamino)-2-oxoethyl)-N-(furan-2-
ylmethyl)pivalamide (0.35 g, 0.83 mmol) in 40 mL of DCM 
was added MnO2 (1.02 g, 11.7 mmol).  After stirring for 24 hours the solution was 
filtered through Celite® and concentrated yielding the product (0.28 g, 0.67 mmol, 23% 
over four steps).  
1
H NMR (500 MHz, CDCl3) δ 11.19 (s, 1H), 9.85 (d, J = 0.7 Hz, 1H), 
8.68 (d, J = 9.0 Hz, 1H), 7.79 (d, J = 2.4 Hz, 1H), 7.70 (dd, J = 9.0, 2.4 Hz, 1H), 7.34 
(dd, J = 1.8, 0.9 Hz, 1H), 6.33 (dd, J = 3.3, 1.8 Hz, 1H), 6.31 (dd, J = 3.3, 0.9 Hz, 1H), 
4.87 (s, 2H), 4.17 (s, 2H), 1.45 (s, 9H). HRMS (ESI) calcd for C19H22BrN2O4
+
 (MH
+
) 
421.0757, found 421.0757. 
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N-(2-(4-bromo-8-oxo-5,6,7,8-tetrahydronaphthalen-1-
ylamino)-2-oxoethyl)-N-(furan-2-ylmethyl)pivalamide (3.15): 
General procedure BB was followed using  8-amino-5-bromo-
3,4-dihydronaphthalen-1(2H)-one (1.15 g, 4.79 mmol), pyridine 
(0.77 mL, 9.56 mmol), bromoacetyl bromide (0.50 mL, 5.7 
mmol).  The workup yielded 2-bromo-N-(4-bromo-8-oxo-5,6,7,8-
tetrahydronaphthalen-1-yl)acetamide (1.67 g) which was used without further 
purification.  
1H NMR (500 MHz, CDCl3) δ 12.80 (s, 1H), 8.56 (d, J = 9.1 Hz, 1H), 7.76 
(d, J = 9.1 Hz, 1H), 4.04 (s, 2H), 3.08 (t, J = 6.2 Hz, 2H), 2.76 (m, 2H), 2.16 (m, 2H). To 
2-bromo-N-(4-bromo-8-oxo-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide (1.67 g) 
and DIPEA (1.21 mL, 6.95 mmol) in DCM (75 mL) was added furfuryl amine (0.61 mL, 
0.67 mmol).  The mixture was allowed to stir overnight, quenched with water (50 mL), 
the organic phase was separated, and the aqueous layer was extracted with DCM (3 x 100 
mL).  The combined organic fractions were washed with brine, dried over Na2SO4, 
filtered, and concentrated yielding N-(4-bromo-8-oxo-5,6,7,8-tetrahydronaphthalen-1-
yl)-2-(furan-2-ylmethylamino)acetamide (1.60 g) which was used without further 
purification  
1H NMR (500 MHz, CDCl3) δ 12.85 (s, 1H), 8.66 (d, J = 9.1 Hz, 1H), 7.73 
(d, J = 9.1 Hz, 1H), 7.38 (dd, J = 1.9, 0.9 Hz, 1H), 6.34 (dd, J = 3.2, 1.7 Hz, 1H), 6.29 
(dd, J = 3.2, 0.8 Hz, 1H), 3.92 (s, 2H), 3.48 (s, 2H), 3.07 (t, J = 6.2 Hz, 2H), 2.73 (m, 
2H), 2.14 (m, 2H). To N-(4-bromo-8-oxo-5,6,7,8-tetrahydronaphthalen-1-yl)-2-
(furan-2-ylmethylamino)acetamide (1.60 g) and DIPEA (0.96 mL, 5.5 mmol) in DCM 
(75 mL) was added pivaloyl chloride (0.68 mL, 5.5 mmol).  The mixture was allowed to 
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stir overnight, quenched with water (75 mL), the organic phase was separated, and the 
aqueous layer was extracted with DCM (3 x 100 mL).  The combined organic fractions 
were dried over Na2SO4, filtered, and concentrated.  Purification by flash 
chromatography yielded 0.43 g (19%) of the product over three steps. 
1
H NMR (500 
MHz, CDCl3) δ 12.35 (s, 1H), 8.57 (d, J = 9.1 Hz, 1H), 7.71 (d, J = 9.1 Hz, 1H), 7.36 
(dd, J = 1.8, 0.9 Hz, 1H), 6.34 (dd, J = 3.2, 1.8 Hz, 1H), 6.29 (dd, J = 3.3, 0.9 Hz, 1H), 
4.85 (s, 2H), 4.18 (s, 2H), 3.05 (t, J = 6.2 Hz, 2H), 2.70 (m, 2H), 2.12 (m, 2H), 1.42 (s, 
9H). 
 13
C NMR (126 MHz, CDCl3) δ 202.6, 178.2, 168.5, 150.1, 144.1, 142.6, 140.8, 
138.7, 120.2, 119.9, 117.9, 110.4, 109.0, 52.0, 46.2, 40.0, 39.2, 31.4, 28.6, 21.7.  HRMS 
(ESI) calcd for C22H26BrN2O4
+
 (MH
+
) 461.1070, found 461.1073. 
 
N-benzyl-N-(2-(4-bromo-8-oxo-5,6,7,8-
tetrahydronaphthalen-1-ylamino)-2-oxoethyl)furan-2-
carboxamide (3.16):  General procedure BB was followed 
using 8-amino-5-bromo-3,4-dihydronaphthalen-1(2H)-one 
(0.42 g, 1.7 mmol), DIPEA (0.36 mL, 2.1 mmol) and 
bromoacetyl bromide (0.18 mL, 2.1 mmol). The workup yielded 2-bromo-N-(4-bromo-
8-oxo-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide (0.70 g) which was used without 
further purification.  
1H NMR (500 MHz, CDCl3) δ 12.80 (s, 1H), 8.56 (d, J = 9.1 Hz, 
1H), 7.76 (d, J = 9.1 Hz, 1H), 4.04 (s, 2H), 3.08 (t, J = 6.2 Hz, 2H), 2.76 (m, 2H), 2.16 
(m, 2H). To 2-bromo-N-(4-bromo-8-oxo-5,6,7,8-tetrahydronaphthalen-1-
yl)acetamide (0.70 g) and DIPEA (0.34 mL, 2.0 mmol) in DCM (40 mL) was added 
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benzyl amine (0.29 mL, 2.7 mmol).  The mixture was allowed to stir overnight, quenched 
with water (50 mL), the organic phase was separated, and the aqueous layer was 
extracted with DCM (3 x 100 mL).  The combined organic fractions were dried over 
Na2SO4, filtered, and concentrated yielding 2-(benzylamino)-N-(4-bromo-8-oxo-5,6,7,8-
tetrahydronaphthalen-1-yl)acetamide (0.88 g) 
 1
H NMR (500 MHz, CDCl3) δ 12.92 (s, 
1H), 8.67 (d, J = 9.1, 0.7 Hz, 1H), 7.72 (d, J = 9.1 Hz, 1H), 7.47 (m, 2H), 7.37 (m, 3H), 
3.93 (s, 2H), 3.50 (s, 2H), 3.07 (t, J = 6.2 Hz, 2H), 2.75 (m, 2H), 2.15 (m, 2H).  To 2-
(benzylamino)-N-(4-bromo-8-oxo-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide (0.88 
g) and DIPEA (0.44 mL, 2.5 mmol) in DCM (45 mL) was added 2-furoyl chloride (0.27 
mL, 2.7 mmol).  The mixture was allowed to stir overnight, quenched with water (50 
mL), the organic phase was separated, and the aqueous layer was extracted with DCM (3 
x 100 mL). The combined organic fractions were dried over Na2SO4, filtered, and 
concentrated. Purification by flash chromatography yielded 0.32 g (39%) of the product 
over three steps.  
1
H NMR (500 MHz, CDCl3) 
1
H NMR (500 MHz, CDCl3) δ 12.68 (m, 
1H), 8.63 (d, J = 8.8 Hz, 1H), 7.74 (d, J = 9.1 Hz, 1H), 7.50 (m, 1H), 7.36 (m, 5H), 7.21 
(m, 1H), 6.51 (m, 1H), 5.04 (m, 2H), 4.28 (m, 2H), 3.05 (m, 2H), 2.69 (m, 2H), 2.12 (m, 
2H). 
 13
C NMR (126 MHz, CDCl3) δ 202.8, 163.5, 144.6, 144.3, 140.7, 138.8, 136.5, 
136.2, 135.0, 129.1, 128.9, 128.9, 128.4, 127.8, 127.8, 120.3, 119.7, 118.1, 111.6, 52.2, 
46.6, 40.0, 31.4, 21.7. HRMS (ESI) calcd for C24H22BrN2O4
+
 (MH
+
) 481.0757, found 
481.0758. 
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N-(2-formyl-4-(pyridin-3-yl)phenyl)-3-(furan-2-
yl)propanamide (3.3b): General procedure for Suzuki 
coupling SPy with pyridine boronic acid using 
pyridine-3-boronic acid (0.39 g, 3.2 mmol), Pd2(dba)3 (0.035 g, 0.038 mmol), PCy3 
(0.027 g, 0.096 mmol), and N-(4-bromo-2-(hydroxymethyl)phenyl)-3-(furan-2-
yl)propanamide (0.61 g, 1.9 mmol), dioxane (5.0 mL), and aqueous K3PO4 (5.0 mmol, 
3.9 mL of a 1.27 M solution) was followed.  The crude 3-(furan-2-yl)-N-(2-
(hydroxymethyl)-4-(pyridin-3-yl)phenyl)propanamide (0.60 g) was used without further 
purification 
1
H NMR (500 MHz, CDCl3) δ 8.81 (s, 1H), 8.63 (s, 1H), 8.56 (dd, J = 4.8, 
1.1 Hz, 1H), 8.25 (d, J = 8.4 Hz, 1H), 7.84 (ddd, J = 7.9, 2.4, 1.6 Hz, 1H), 7.52 (dd, J = 
8.4, 2.2 Hz, 1H), 7.37 (m, 3H), 6.33 (dd, J = 3.2, 1.9 Hz, 1H), 6.13 (dd, J = 3.1, 0.6 Hz, 
1H), 4.75 (s, 2H), 3.14 (t, J = 7.5 Hz, 2H), 2.81 (t, J = 7.5 Hz, 2H), 1.41 (s, 1H).  To a 
stirred solution of 3-(furan-2-yl)-N-(2-(hydroxymethyl)-4-(pyridin-3-
yl)phenyl)propanamide (0.60 g, 1.9 mmol) in DCM (45 mL) was added MnO2 (2.28 g, 
26.2 mmol). After 24 hours, the solution was filtered through Celite®, concentrated, and 
purified by flash chromatography yielding 0.31g (51%) of the product over two steps. 
 1
H 
NMR (500 MHz, CDCl3) δ 11.22 (s, 1H), 10.05 (s, 1H), 8.92 (d, J = 8.7 Hz, 1H), 8.90 
(dd, J = 2.4, 0.9 Hz, 1H), 8.66 (dd, J = 4.8, 1.6 Hz, 1H), 7.91 (m, 2H), 7.86 (dd, J = 8.7, 
2.3 Hz, 1H), 7.43 (ddd, J = 7.9, 4.8, 0.9 Hz, 1H), 7.35 (dd, J = 1.9, 0.9 Hz, 1H), 6.31 (dd, 
J = 3.2, 1.9 Hz, 1H), 6.11 (m, 1H), 3.14 (m, 2H), 2.88 (m, 2H).  
13
C NMR (126 MHz, 
CDCl3) δ 195.3, 171.3, 153.9, 149.0, 147.9, 141.3, 140.6, 134.6, 134.5, 134.2, 133.9, 
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132.6, 123.7, 122.0, 120.8, 110.2, 105.6, 36.6, 23.6. HRMS (ESI) calcd for C19H17N2O3
+
 
(MH
+
) 321.1234, found 321.1241. 
 
Irradiation and Suzuki coupling of the photoproducts 
 
General Scheme and Procedure for the Irradiation and Subsequent Coupling of Bromo-
Substituted Aromatic Compounds with Pyridine-3-Boronic Acid 
 
 
 
General procedure for irradiation (I):  Solutions with ca. 6.0 mM of the 
photoprecursors 3.3a-3.3e, 3.9, 3.12-3.16 in 5% aq. acetonitrile were degassed by 
sparging with N2 and irradiated in Pyrex or borosilicate glass reaction vessels in a 
Rayonet reactor equipped with RPR-3500 UV lamps (broadband 300-400 nm UV source 
with peak emission at 350 nm) until the reaction was complete, as determined by 
1
H 
NMR.  The solution was concentrated and the cycloaddition products were used without 
further purification. 
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General procedure for Suzuki coupling with pyridine-3-boronic acid (SPy): 
Aqueous K3PO4 (1.70 mmol, 1.33 mL of a 1.27 M solution), degassed by sparging with 
N2 for 30 min, was added to the reaction mixture containing pyridine-3-boronic acid (1.1 
mmol, 1.1 eq), Pd2(dba)3 (0.01 mmol, 0.9mol%), PCy3 (0.024 mmol, 2.2 mol%), and the 
heteroaryl bromide (1.0 mmol, 1.0 eq) in dioxane (2.67 mL) under nitrogen atmosphere.  
The mixture was refluxed for 36 hours with vigorous stirring, cooled to room 
temperature, filtered through a layer of silica gel using extra allotments of EtOAc, 
concentrated, diluted with water (40 mL) and extracted with EtOAc (3 x 75 mL).  The 
combined organic fractions were dried over Na2SO4, filtered, concentrated, and the 
product(s) were purified using flash chromatography yielding the isolated coupling 
products.   
 
General procedure for Suzuki coupling with phenylboronic acid (SPh): The 
heteroaryl halide (0.94 mmol, 1eq) and Pd(PPh3)4 (5.3 mol%, 0.050 mmol), were 
suspended in dimethoxyethane (4 mL) the  mixture was allowed to stir under nitrogen 
atmosphere for 10 min.  Phenylboronic acid (1.17 eq, 1.1 mmol) followed by aq. Na2CO3 
(1.06 mL, 2 M solution, 2.12 mmol) were added to the mixture, and the resulting solution 
was refluxed under nitrogen atmosphere for 24 hours.  The mixture was allowed to cool 
to room temperature, extracted with Et2O (6 x 40 mL), and the combined organic 
fractions were washed with water, dried over Na2SO4, concentrated, and subjected to 
flash chromatography. 
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General procedure for Suzuki coupling with thiophene-2- and furan-2-
boronic acids (STF): To a stirred mixture of the heteroaryl iodide (0.20 g, 0.54 mmol) 
and Pd(PPh3)4 (5.2-5.8 mol%, 0.032 g, 0.028 mmol) in DME (16 mL) was added 
thiophene-2- or furan-2-boronic acid (0.077 g, 0.60 mmol).  The mixture was placed 
under nitrogen atmosphere, and NaHCO3 (0.095 g, 1.1 mmol) in H2O (16 mL) was 
added.  The reaction mixture was heated under reflux with vigorous stirring for 12 hours.  
Subsequently, the organic solvent was removed under reduced pressure, an extraction 
was performed on the remaining aqueous layer using EtOAc (5 x 25 mL), the combined 
organic fractions were dried using MgSO4, filtered, concentrated, and subjected to flash 
chromatography. 
 
8-Hydroxy-5-phenyl-12-oxa-1-
azatetracyclo[11.3.0.0
2,7
.0
9,13
]hexadeca-2,4,6,10-tetraen-16-
one (3.4f): General procedure I was followed. From N-(4-
bromo-2-formylphenyl)-3-(furan-2-yl)propanamide (3.3a) 
(1.0 g, 3.1 mmol) a mixture 5-bromo-8-hydroxy-12-oxa-1-
azatetracyclo[11.3.0.0
2,7
.0
9,13
]hexadeca-2,4,6,10-tetraen-16-one (3.4a) and 5-bromo-2-
hydroxy-16-oxa-9-azatetracyclo[11.2.1.0
3,8
.0
5,9
]hexadeca-3,5,7,14-tetraen-10-one 
(3.5a) in the ratio of 1:1 was formed, which was introduced into Suzuki coupling 
following the general procedure SPh.  From 0.3 g of that mixture (0.94 mmol), 
phenylboronic acid (0.13 g, 1.1 mmol), Pd(PPh3)4 (0.058 g, 0.05 mmol) Na2CO3 (1.06 
mL of a 2 M solution, 2.12 mmol) 0.089 g (30%) of the title compound and  0.13 g (44%) 
  
69 
of 2-hydroxy-5-phenyl-16-oxa-9-azatetracyclo[11.2.1.0
3,8
.0
5,9
]hexadeca-3,5,7,14-
tetraen-10-one (3.5f) were isolated.
  1
H NMR (500 MHz, CDCl3) δ 7.98 (d, J = 8.3 Hz, 
1H), 7.64 (dd, J = 8.3, 2.1 Hz, 1H), 7.59 (m, 2H), 7.46 (m, 3H), 7.38 (m, 1H), 6.27 (t, J = 
2.8 Hz, 1H), 4.84 (d, J = 2.1 Hz, 1H), 4.70 (dd, J = 3.1, 2.2 Hz, 1H), 3.89 (q, J = 2.3 Hz, 
1H), 2.86 (m, 1H), 2.59 (m, 1H), 2.47 (m, 2H), 2.19(s, 1H).  
13
C NMR (126 MHz, 
CDCl3) δ 173.4, 146.7, 140.1, 138.8, 133.3, 131.3, 128.9, 128.2, 127.5, 127.4, 126.9, 
123.5, 101.4, 99.4, 70.5, 56.1, 35.2, 29.8.  HRMS (ESI) calcd for C20H18NO3
+
 (MH
+
) 
320.1281, found 320.1281. 
 
2-Hydroxy-5-phenyl-16-oxa-9-
azatetracyclo[11.2.1.0
3,8
.0
5,9
]hexadeca-3,5,7,14-tetraen-10-one 
(3.5f):  General procedure I was followed. From N-(4-bromo-2-
formylphenyl)-3-(furan-2-yl)propanamide (3.3a) (1.0 g, 3.1 mmol) a 5-bromo-8-
hydroxy-12-oxa-1-azatetracyclo[11.3.0.0
2,7
.0
9,13
]hexadeca-2,4,6,10-tetraen-16-one 
(4a) and 5-bromo-2-hydroxy-16-oxa-9-azatetracyclo[11.2.1.0
3,8
.0
5,9
]hexadeca-
3,5,7,14-tetraen-10-one (3.5a) in the ratio of 1:1  was formed, which was introduced into 
Suzuki coupling following the general procedure SPh  From 0.3 g of the mixture (0.94 
mmol), phenylboronic acid (0.13 g, 1.1 mmol), Pd(PPh3)4 (0.058g, 0.05 mmol) Na2CO3 
(1.06 mL of a 2 M solution, 2.12 mmol) 0.13 g (44%) of the title compound and 0.089 g 
(30%) of 8-hydroxy-5-phenyl-12-oxa-1-azatetracyclo[11.3.0.0
2,7
.0
9,13
]hexadeca-
2,4,6,10-tetraen-16-one (3.4f) was isolated. 
 1
H NMR (500 MHz, CDCl3) δ 7.60 (m, 4H), 
7.54 (m, 1H), 7.45 (m, 2H), 7.38 (m, 1H), 6.36 (dd, J = 5.9, 1.9 Hz, 1H), 5.70 (dd, J = 
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5.8, 1.1 Hz, 1H), 5.09 (m, 1H), 4.75 (d, J = 7.0 Hz, 1H), 3.15 (s, 1H), 2.89 (m, 1H), 2.65 
(m, 1H), 2.57 (dt, J=13.8, 9.8, 1H), 2.48 (ddd, J=13.9, 9.5, 1.7, 1H) .  
13
C NMR (126 
MHz, CDCl3) δ 173.2, 139.9, 139.5, 134.8, 133.5, 131.6, 131.2, 129.3, 128.8, 128.0, 
127.5, 127.2, 127.0, 103.6, 83.7, 79.5, 30.0, 28.9.  HRMS (ESI) calcd for C20H18NO3
+
 
(MH
+
) 320.1281, found 320.1283. 
 
 
 
8-Hydroxy-5-pyridin-3-yl-12-oxa-1-
azatetracyclo[11.3.0.0
2,7
.0
9,13
] hexadeca-2,4,6,10-tetraen-16-
one (3.4b): Pathway A: 0.25 g (0.78 mmol) of N-(2-formyl-4-
(pyridin-3-yl)phenyl)-3-(furan-2-yl)propanamide (3.3b) was irradiated following the 
general procedure I.  Flash chromatography resulted in an isolated yield of 0.12 g (47%) 
of the title compound and 0.10g (40%) of 2-Hydroxy-5-pyridin-2-yl-16-oxa-9-
azatetracyclo[11.2.1.0
3,8
.0
5,9
]hexadeca-3,5,7,14-tetraen-10-one (3.5b).   
Pathway B:  0.34 g (1.1 mmol) of N-(4-bromo-2-formylphenyl)-3-(furan-2-
yl)propanamide (3.3a) was irradiated following general procedure I yielding a mixture 
of a 5-bromo-8-hydroxy-12-oxa-1-azatetracyclo[11.3.0.0
2,7
.0
9,13
]hexadeca-2,4,6,10-
tetraen-16-one (3.4a) and 5-bromo-2-hydroxy-16-oxa-9-
azatetracyclo[11.2.1.0
3,8
.0
5,9
]hexadeca-3,5,7,14-tetraen-10-one (3.5a) in the ratio of 
1:1.  0.34 g of the mixture was then introduced into Suzuki coupling following general 
procedure SPy using pyridine-3-boronic acid (0.23 g, 1.9 mmol), Pd2(dba)3 (0.021 g, 
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0.023 mmol), PCy3 (0.016 g, 0.057 mmol), dioxane (3.1 mL), and aqueous K3PO4 (2.86 
mmol, 2.3 mL of a 1.27 M solution) resulting in an isolated yield of 0.024 g, (6.8%) of 
the title compound and  0.10 g (28%) of 2-Hydroxy-5-pyridin-2-yl-16-oxa-9-
azatetracyclo[11.2.1.0
3,8
.0
5,9
]hexadeca-3,5,7,14-tetraen-10-one (3.5b) 
1
H NMR (500 
MHz, CDCl3) δ 8.64 (d, J = 2.4 Hz, 1H), 8.56 (dd, J = 4.8, 1.6 Hz, 1H), 8.05 (d, J = 8.3 
Hz, 1H), 7.83 (ddd, J = 8.0, 2.4, 1.6 Hz, 1H), 7.57 (dd, J = 8.3, 2.1 Hz, 1H), 7.41 (d, J = 
2.1 Hz, 1H), 7.36 (ddd, J = 8.0, 4.8, 0.9 Hz, 1H), 6.29 (t, J = 2.8 Hz, 1H), 4.88 (d, J = 2.2 
Hz, 1H), 4.71 (dd, J = 3.1, 2.3 Hz, 1H), 3.93 (q, J = 2.3 Hz, 1H), 2.90 (ddd, J = 16.1, 
10.3, 8.2 Hz, 1H), 2.56 (m, 3H), 1.64 (s, 1H).  
13
C NMR (126 MHz, CDCl3) δ 173.3, 
148.4, 148.0, 146.8, 135.7, 135.1,134.4, 134.2, 131.8, 128.2, 127.4, 123.8, 123.6, 101.4, 
99.4, 70.3, 56.1, 35.2, 29.8 HRMS (ESI) calcd for C19H17N2O3
+
 (MH
+
) 321.1234, found 
321.1241. 
 
2-Hydroxy-5-pyridin-2-yl-16-oxa-9-
azatetracyclo[11.2.1.0
3,8
.0
5,9
]hexadeca-3,5,7,14-tetraen-10-one 
(3.5b): Pathway A: 0.25 g (0.78 mmol) of N-(2-formyl-4-
(pyridin-3-yl)phenyl)-3-(furan-2-yl)propanamide was irradiated 
following the general procedure I.  Flash chromatography resulted in an isolated yield of 
0.12 g (47%) of 8-hydroxy-5-(pyridin-3-yl)-12-oxa-1-
azatetracyclo[11.3.0.0
2,7
.0
9,13
]hexadeca-2,4,6,10-tetraen-16-one (3.4b) and 0.10 g 
(40%) of the title compound. 
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Pathway B: 0.34 g (1.1 mmol) of N-(4-Bromo-2-formylphenyl)-3-(furan-2-
yl)propanamide (3.3a) was irradiated following general procedure for irradiation 
yielding a mixture of a 5-bromo-8-hydroxy-12-oxa-1-
azatetracyclo[11.3.0.0
2,7
.0
9,13
]hexadeca-2,4,6,10-tetraen-16-one (4a) and 5-bromo-2-
hydroxy-16-oxa-9-azatetracyclo[11.2.1.0
3,8
.0
5,9
]hexadeca-3,5,7,14-tetraen-10-one 
(3.5a) in the ratio of 1:1.  0.34 g of the mixture was then subjected to general procedure 
SPy  using pyridine-3-boronic acid (0.23 g, 1.9 mmol), Pd2(dba)3 (0.021 g, 0.023 mmol), 
PCy3 (0.016 g, 0.057 mmol), dioxane (3.1 mL), and aqueous K3PO4 (2.86 mmol, 2.3 mL , 
1.27 M solution) resulting in an isolated yield of 0.024 g (6.8%) of 8-hydroxy-5-pyridin-
3-yl-12-oxa-1-azatetracyclo[11.3.0.0
2,7
.0
9,13
]hexadeca-2,4,6,10-tetraen-16-one (3.4b) 
and 0.10 g (28%) of the title compound. 
1
H NMR (500 MHz, CDCl3) δ 8.83 (d, J = 2.1 
Hz, 1H), 8.61 (dd, J = 4.8, 1.6 Hz, 1H), 7.88 (dt, J = 8.0, 1.9 Hz, 1H), 7.65 (d, J = 8.3 Hz, 
1H), 7.58 (dd, J = 8.4, 2.2 Hz, 1H), 7.53 (d, J = 2.2 Hz, 1H), 7.39 (ddd, J = 7.9, 4.8, 0.9 
Hz, 1H), 6.38 (dd, J = 5.8, 1.8 Hz, 1H), 5.71 (dd, J = 5.8, 1.2 Hz, 1H), 5.10 (m, 1H), 4.76 
(d, J = 3.3 Hz, 1H), 2.91 (dt, J = 17.2, 9.7 Hz, 1H), 2.67 (ddd, J=17.2, 9.8, 1.8, 1H), 2.58 
(dt, J=13.8, 9.8, 1H), 2.50 (ddd, J=13.8, 9.5, 1.8, 1H). 
13
C NMR (126 MHz, CDCl3) δ 
173.3, 148.7, 148.1, 136.0, 135.4, 134.8, 134.2, 133.9, 132.5, 131.2, 129.3, 128.4, 127.2, 
123.6, 103.6, 83.6, 79.4, 30.0, 28.9.  HRMS (ESI) calcd for C19H17N2O3
+
 (MH
+
) 
321.1234, found 321.1241. 
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8-Hydroxy-6-(pyridin-3-yl)-12-oxa-1-
azatetracyclo[11.3.0.0
2,7
.0
9,13
] hexadeca-2,4,6,10-tetraen-16-
one (3.17b):  General procedure I was followed using 0.25 g 
(0.78 mmol) of N-(5-bromo-2-formylphenyl)-3-(furan-2-
yl)propanamide (3.9)  yielding a mixture of 6-bromo-8-hydroxy-12-oxa-1-
azatetracyclo[11.3.0.0
2,7
.0
9,13
]hexadeca-2,4,6,10-tetraen-16-one (3.17a) and 6-bromo-
2-hydroxy-16-oxa-9-azatetracyclo[11.2.1.0
3,8
.0
5,9
]hexadeca-3,5,7,14-tetraen-10-one 
(3.18a) in the ratio of 1:0.8. 0.25 g of the mixture was then subjected to general 
procedure for Suzuki coupling SPy  using pyridine-3-boronic acid (0.14 g, 1.1 mmol), 
Pd2(dba)3 (0.014 g, 0.015 mmol), PCy3 (0.012 g, 0.043 mmol), dioxane (2.25 mL), and 
aqueous K3PO4 (0.73 mmol, 0.97 mL of a 1.27 M solution) resulting in an isolated yield 
of 0.072 g (28%) of the title compound and 0.059 g (23%) of 2-hydroxy-6-(pyridin-3-
yl)-16-oxa-9-azatetracyclo[11.2.1.0
3,8
.0
5,9
]hexadeca-3,5,7,14-tetraen-10-one (3.18b)
 1
H 
NMR (500 MHz, CDCl3) δ 8.53 (d, J = 4.8 Hz, 1H), 8.41 (s, 1H), 8.12 (d, J = 1.7 Hz, 
1H), 7.89 (ddd, J = 7.9, 2.4, 1.6 Hz, 1H), 7.33 (m, 2H), 6.28 (t, J = 2.8 Hz, 1H), 4.86 (d, J 
= 2.2 Hz, 1H), 4.71 (dd, J = 3.0, 2.2 Hz, 1H), 3.93 (q, J = 2.4 Hz, 1H), 2.88 (m, 1H), 2.56 
(m, 4H), 1.64 (s, 1H). 
13
C NMR (126 MHz, CDCl3) δ 173.3, 148.3, 148.0, 146.7, 139.1, 
135.0, 134.7, 131.0, 129.5, 124.3, 123.6, 121.9, 101.5, 99.5, 69.8, 56.2, 35.2, 29.9.  
HRMS (ESI) calcd for C19H17N2O3
+
 (MH
+
) 321.1234, found 321.1237. 
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2-Hydroxy-6-(pyridin-3-yl)-16-oxa-9-
azatetracyclo[11.2.1.0
3,8
.0
5,9
]hexadeca-3,5,7,14-tetraen-10-one 
(3.18b):  General procedure I was followed using 0.25 g (0.78 
mmol) of N-(5-bromo-2-formylphenyl)-3-(furan-2-
yl)propanamide (3.9) yielding a mixture of 6-bromo-8-hydroxy-12-oxa-1-
azatetracyclo[11.3.0.0
2,7
.0
9,13
]hexadeca-2,4,6,10-tetraen-16-one (3.17a) and 6-bromo-
2-hydroxy-16-oxa-9-azatetracyclo[11.2.1.0
3,8
.0
5,9
]hexadeca-3,5,7,14-tetraen-10-one 
(3.18a)  in the ratio of 1:0.8.  0.25 g of the mixture was then subjected to general 
procedure for Suzuki coupling SPy  using  pyridine-3-boronic acid (0.14 g, 1.1 mmol), 
Pd2(dba)3 (0.014 g, 0.015 mmol), PCy3 (0.012 g, 0.043 mmol), dioxane (2.25 mL), and 
aqueous K3PO4 (0.73 mmol, 0.97 mL of a 1.27 M solution) resulting in an isolated yield 
of 0.072 g (28%) of 8-hydroxy-6-(pyridin-3-yl)-12-oxa-1-
azatetracyclo[11.3.0.0
2,7
.0
9,13
]hexadeca-2,4,6,10-tetraen-16-one (3.17b) and 0.059 g 
(23%) of the title compound.
  1
H NMR (500 MHz, CDCl3) δ 8.84 (s, 1H), 8.61 (s, 1H), 
7.91 (dt, J = 8.0, 2.0 Hz, 1H), 7.76 (d, J = 1.8 Hz, 1H), 7.43 (m, 2H), 7.38 (t, J = 7.5, 4.8 
Hz, 1H), 6.37 (dd, J = 5.9, 1.9 Hz, 1H), 5.71 (dd, J = 5.9, 1.2 Hz, 1H), 5.08 (m, 1H), 4.73 
(s, 1H), 3.17 (s, 1H), 2.94 (m, 1H), 2.68 (ddd, J = 17.3, 9.8, 1.8 Hz, 1H), 2.58 (dt, J=13.9, 
9.8, 1H), 2.50 (ddd, J=13.9, 9.5, 1.8, 1H). 
13
C NMR (126 MHz, CDCl3) δ 173.1, 148.8, 
148.2, 138.2, 134.8, 134.5, 133.4, 133.2, 132.8, 129.3, 126.4, 125.1, 123.6, 103.7, 83.6, 
79.0, 30.1, 28.9.  HRMS (ESI) calcd for C19H17N2O3
+
 (MH
+
) 321.1234, found 321.1240. 
 
  
75 
8-Hydroxy-8-methyl-5-(pyridin-3-yl)-12-oxa-1-
azatetracyclo [11.3.0.0
2,7
.0
9,13
]hexadeca-2,4,6,10-tetraen-16-
one (3.19b): General procedure I was followed using 0.50 g 
(1.5 mmol) of N-(2-acetyl-4-bromophenyl)-3-(furan-2-
yl)propanamide (3.10) yielding 0.50 g of a mixture of 5-bromo-8-hydroxy-8-methyl-
12-oxa-1-azatetracyclo[11.3.0.0
2,7
.0
9,13
]hexadeca-2,4,6,10-tetraen-16-one (3.19a) and 
5-bromo-2-hydroxy-2-methyl-16-oxa-9-azatetracyclo[11.2.1.0
3,8
.0
5,9
]hexadeca-
3,5,7,14-tetraen-10-one (3.20a) in the ratio of 1:1. 0.25 g of the mixture was then 
subjected to general procedure for Suzuki coupling SPy  using pyridine-3-boronic acid 
(0.14 g, 1.1 mmol), Pd2(dba)3 (0.014 g, 0.015 mmol), PCy3 (0.012 g, 0.043 mmol), 
dioxane (2.25 mL), and aqueous K3PO4 (0.73 mmol, 0.97 mL of a 1.27 M solution) 
resulting in an isolated yield of 0.071 g, (28%) of the title compound and 0.072 g (30%) 
of 2-Hydroxy-2-methyl-3,4-(4’-pyridin-3-yl)benzo-12-oxa-5-aza-
tricyclo[7.2.1.0
5,9
]dodec-3,10-dien-6-one (3.20b). 
1
H NMR (500 MHz, CDCl3) δ 8.43 
(dd, J = 4.8, 1.7 Hz, 1H), 8.22 (d, J = 2.4 Hz, 1H), 7.94 (d, J = 8.2 Hz, 1H), 7.73 (ddd, J 
= 7.9, 2.4, 1.6 Hz, 1H), 7.43 (dd, J = 8.2, 2.0 Hz, 1H), 7.38 (d, J = 2.1 Hz, 1H), 7.28 (dd, 
J = 7.8, 4.8 Hz, 1H), 6.25 (t, J = 2.8 Hz, 1H), 4.65 (dd, J = 3.1, 2.2 Hz, 1H), 4.18 (s, 1H), 
3.74 (t, J = 2.4 Hz, 1H), 2.85 (m, 1H), 2.52 (m, 3H), 1.79 (s, 3H).  
13
C NMR (126 MHz, 
CDCl3) δ 173.3, 147.9, 147.8, 146.9, 136.1, 134.9, 134.5, 134.3, 134.3, 127.4, 124.1, 
123.7, 123.5, 101.6, 99.1, 70.5, 61.3, 35.1, 29.8, 25.4.  HRMS (ESI) calcd for 
C20H19N2O3
+
 (MH
+
) 335.1390, found 335.1396. 
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2-Hydroxy-2-methyl-5-(pyridin-3-yl)-16-oxa-9-
azatetracyclo[11.2.1.0
3,8
.0
5,9
] hexadeca-3,5,7,14-tetraen-10-one 
(3.20b): General procedure I was performed using 0.50 g (1.5 
mmol) of N-(2-acetyl-4-bromophenyl)-3-(furan-2-yl)propanamide (3.10) yielding 
0.50 g of a mixture of 5-bromo-8-hydroxy-8-methyl-12-oxa-1-
azatetracyclo[11.3.0.0
2,7
.0
9,13
]hexadeca-2,4,6,10-tetraen-16-one (3.19a) and 5-bromo-
2-hydroxy-2-methyl-16-oxa-9-azatetracyclo[11.2.1.0
3,8
.0
5,9
]hexadeca-3,5,7,14-
tetraen-10-one (3.20a) in the ratio of 1:1.  0.25 g of the mixture was then subjected to 
general procedure for Suzuki coupling SPy  using pyridine-3-boronic acid (0.14 g, 1.1 
mmol), Pd2(dba)3 (0.014 g, 0.015 mmol), PCy3 (0.012 g, 0.043 mmol), dioxane (2.25 
mL), and aqueous K3PO4 (0.73 mmol, 0.97 mL of a 1.27 M solution) resulting in an 
isolated yield of 0.071 g, (28%) of 8-hydroxy-8-methyl-5-(pyridin-3-yl)-12-oxa-1-
azatetracyclo[11.3.0.0
2,7
.0
9,13
]hexadeca-2,4,6,10-tetraen-16-one (3.19b) and 0.072 g 
(30%) of the title compound.  
1
H NMR (500 MHz, CDCl3) δ 8.84 (s, 1H), 8.63 (s, 1H), 
7.87 (dt, J = 8.1, 1.8 Hz, 1H), 7.72 (d, J = 1.9 Hz, 1H), 7.56 (m, 2H), 7.40 (dd, J = 8.0, 
4.7 Hz, 1H), 6.37 (dd, J = 5.9, 1.9 Hz, 1H), 5.72 (dd, J = 5.8, 1.1 Hz, 1H), 4.78 (t, J = 1.4 
Hz, 1H), 3.57 (s, 1H), 2.95 (dt, J = 17.4, 9.8 Hz, 1H), 2.69 (ddd, J = 17.4, 9.7, 1.8 Hz, 
1H), 2.57 (dt, J=13.9, 9.9, 1H), 2.49 (ddd, J=13.9, 9.5, 1.8, 1H), 1.80 (s, 3H).
  13
C NMR 
(126 MHz, CDCl3) δ 173.0, 148.6, 148.2, 137.1, 136.0, 136.0, 134.8, 134.3, 132.6, 129.3, 
129.0, 126.9, 126.4, 123.6, 103.4, 89.2, 78.0, 30.2, 28.5, 24.7.  HRMS (ESI) calcd for 
C20H19N2O3
+
 (MH
+
) 335.1390, found 335.1398.   
. 
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11-Hydroxy-16-(pyridine-3-yl)-7-oxa-2-azapentacyclo 
[9.7.1.0
2,6
.0
6,10
.0
15,19
]nonadeca-1(19),8,15(16),17-tetraen-3-
one (3.21b):  General procedure I was performed using 0.36 g 
(0.99 mmol) of N-(4-bromo-8-oxo-5,6,7,8-
tetrahydronaphthalen-1-yl)-3-(furan-2-yl)propanamide (3.11) yielding a mixture of 
11-hydroxy-16-bromo-7-oxa-2-azapentacyclo[9.7.1.0
2,6
.0
6,10
.0
15,19
]nonadeca-
1(19),8,15(16),17-tetraen-3-one (3.21a) and 10-hydroxy-15-bromo-9-oxa-2-
azapentacyclo[8.7.1.1
6,9
.0
2,6
.0
14,18
]nonadeca-1(18),7,14(15),16(17)tetraen-3-one 
(3.22a) in the ratio of 1:1.9.  0.36 g of the mixture was then subjected to general 
procedure SPy using pyridine-3-boronic acid (0.14 g, 1.1 mmol), Pd2(dba)3 (0.011 g, 
0.012 mmol), PCy3 (0.078 g, 0.028 mmol), dioxane (3.1 mL), and aqueous K3PO4 (1.70 
mmol, 1.34 mL of a 1.27 M solution) resulting in an isolated yield of 0.13 g, (36%) of the 
title compound  and 0.057 g (16%) of  10-Hydroxy-15-(pyridine-3-yl)-9-oxa-2-
azapentacyclo[8.7.1.1
6,9
.0
2,6
.0
14,18
]nonadeca-1(18),7,14(15),16(17)tetraen-3-one 
(3.22b).  
1
H NMR (500 MHz, CDCl3) δ 8.52 (dd, J = 4.8, 1.6 Hz, 1H), 8.04 (s, 1H), 7.81 
(d, J = 8.2 Hz, 1H), 7.62 (ddd, J = 7.8, 2.3, 1.6 Hz, 1H), 7.32 (ddd, J = 7.8, 4.8, 0.9 Hz, 
1H), 7.21 (d, J = 8.2 Hz, 1H), 6.33 (t, J = 2.8 Hz, 1H), 4.76 (dd, J = 3.2, 2.2 Hz, 1H), 
3.78 (t, J = 2.4 Hz, 1H), 2.90 (m, 1H), 2.58 (m, 6H), 2.05 (m, 1H), 1.92 (td, J = 13.0, 3.4 
Hz, 1H), 1.84 (m, 1H), 1.67 (s, 1H).  
13
C NMR (126 MHz, CDCl3) δ 173.4, 149.6, 147.9, 
146.8, 136.7, 136.6, 135.7, 135.1, 134.2, 130.0, 129.6, 122.9, 121.5, 101.5, 99.4, 69.5, 
60.0, 41.0, 35.2, 29.8, 28.7, 18.4.  HRMS (ESI) calcd for C22H21N2O3
+
 (MH
+
) 361.1547, 
found 361.1550. 
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10-Hydroxy-15-(pyridine-3-yl)-9-oxa-2-
azapentacyclo[8.7.1.1
6,9
.0
2,6
.0
14,18
] nonadeca-
1(18),7,14(15),16(17)tetraen-3-one (3.22b):  General procedure I 
was followed using 0.36 g (0.99 mmol) of N-(4-bromo-8-oxo-
5,6,7,8-tetrahydronaphthalen-1-yl)-3-(furan-2-yl)propanamide (3.11) yielding a 
mixture of 11-hydroxy-16-bromo-7-oxa-2-
azapentacyclo[9.7.1.0
2,6
.0
6,10
.0
15,19
]nonadeca-1(19),8,15(16),17-tetraen-3-one (3.21a) 
and 10-hydroxy-15-bromo-9-oxa-2-azapentacyclo[8.7.1.1
6,9
.0
2,6
.0
14,18
]nonadeca-
1(18),7,14(15),16(17)tetraen-3-one (3.22a) in the ratio of 1:1.9.  0.36 g of the mixture 
was then subjected to general procedure SPy using pyridine-3-boronic acid (0.14 g, 1.1 
mmol), Pd2(dba)3 (0.011 g, 0.012 mmol), PCy3 (0.078 g, 0.028 mmol), dioxane (3.1 mL), 
and aqueous K3PO4 (1.70 mmol, 1.34 mL of a 1.27M solution) resulting in an isolated 
yield of 0.13 g, (36%) of 11-hydroxy-16-(pyridine-3-yl)-7-oxa-2-
azapentacyclo[9.7.1.0
2,6
.0
6,10
.0
15,19
]nonadeca-1(19),8,15(16),17-tetraen-3-one (3.21b) 
and 0.057 g (16%) of  the title compound.  
1
H NMR (500 MHz, CDCl3) δ 8.61 (dd, 
J=4.9, 1.7, 1H), 8.55 (dd, J=2.3, 0.9, 1H), 7.61 (dt, J=7.8, 2.0, 1H), 7.36 (ddd, J=7.8, 4.9, 
0.9, 1H), 7.28 (m, 1H), 7.15 (d, J=8.1, 1H), 6.43 (dd, J=5.8, 1.9, 1H), 5.76 (dd, J=5.9, 
1.1, 1H), 4.62 (m, 1H), 3.51 (s, 1H), 3.03 (ddd, J=17.4, 10.3, 9.2, 1H), 2.71 (ddd, J=17.5, 
9.6, 1.7, 1H), 2.56 (m, 4H), 2.09 (m, 1H), 1.99 (m, 1H), 1.77 (m, 1H), 1.69 (td, J=13.5, 
3.1, 1H). 
13
C NMR (126 MHz, CDCl3) δ 173.1, 149.9, 148.3, 137.5, 137.3, 136.5, 136.2, 
135.3, 133.8, 129.6, 129.3, 126.4, 123.1, 103.2, 88.0, 75.4, 35.8, 30.4, 30.3, 29.7, 28.6, 
17.8.  HRMS (ESI) calcd for C22H21N2O3
+
 (MH
+
) 361.1547, found 361.1553. 
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8-Hydroxy-5-pyridin-3-yl-15-pivaloyl-12-oxa-1,15-
diazatetracyclo [11.3.0.0
2,7
.0
9,13
]heptadeca-2,4,6,10-
tetraen-17-one (3.23b): General procedure I  was followed 
using 0.26 g (0.62 mmol) of N-(2-(4-bromo-2-
formylphenylamino)-2-oxoethyl)-N-(furan-2-
ylmethyl)pivalamide (3.14) yielding a mixture of  5-bromo-8-hydroxy-15-pivaloyl-12-
oxa-1,15-diazatetracyclo[11.3.0.0
2,7
.0
9,13
]heptadeca-2,4,6,10-tetraen-17-one (3.23a) 
and 5-bromo-2-hydroxy-12-pivaloyl-17-oxa-9,12-
diazatetracyclo[11.2.1.0
3,8
.0
5,9
]heptadeca-3,5,7,15-tetraen-10-one (3.24a) in the ratio 
of 1:1.4. 0.26 g of the mixture was then subjected to general procedure SPy using 
pyridine-3-boronic acid (0.086 g, 0.70 mmol), Pd2(dba)3 (0.0063 g, 0.0069 mmol), PCy3 
(0.0046 g, 0.016 mmol), dioxane (2.0 mL), and aqueous K3PO4 (1.1 mmol, 0.84 mL of a 
1.27 M solution) resulting in an isolated yield of 0.050 g, (19%) of the title compound 
and 0.030 g (12%) of 2-hydroxy-12-pivaloyl-5-(pyridin-3-yl)-17-oxa-9,12-
diazatetracyclo[11.2.1.0
3,8
.0
5,9
]heptadeca-3,5,7,15-tetraen-10-one (3.24b). 
1
H NMR 
(500 MHz, CDCl3) δ 8.53 (d, J = 4.3 Hz, 1H), 8.44 (s, 1H), 7.81 (ddd, J = 7.9, 2.4, 1.6 
Hz, 1H), 7.75 (d, J = 8.3 Hz, 1H), 7.54 (dd, J = 8.3, 2.2 Hz, 1H), 7.34 (t, J = 7.8, 4.9 Hz, 
1H), 7.32 (d, J = 2.2 Hz, 1H), 6.22 (t, J = 2.7 Hz, 1H), 5.09 (d, J = 18.7 Hz, 1H), 4.76 
(dd, J = 3.1, 2.3 Hz, 1H), 4.75 (d, J = 2.2 Hz, 1H), 4.67 (dd, J = 13.9, 1.9 Hz, 1H), 4.14 
(d, J = 18.7 Hz, 1H), 3.81 (d, J = 13.9 Hz, 1H), 3.70 (q, J = 2.3 Hz, 1H), 1.66 (s, 1H),1.36 
(s, 9H). 
 13
C NMR (126 MHz, CDCl3) δ 176.5, 164.9, 148.4, 147.9, 146.9, 135.9, 135.5, 
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134.6, 134.3, 133.9, 127.9, 127.8, 127.2, 123.6, 99.8, 94.9, 68.9, 55.1, 51.7, 50.2, 38.9, 
28.3. HRMS (ESI) calcd for C24H26N3O4
+
 (MH
+
) 420.1918, found 420.1921. 
 
2-Hydroxy-12-pivaloyl-5-(pyridin-3-yl)-17-oxa-9,12-
diazatetracyclo [11.2.1.0
3,8
.0
5,9
]heptadeca-3,5,7,15-
tetraen-10-one (3.24b): General procedure I was performed 
using 0.26 g (0.62 mmol) of N-(2-(4-bromo-2-
formylphenylamino)-2-oxoethyl)-N-(furan-2-
ylmethyl)pivalamide (3.14) yielding a mixture of 5-bromo-8-hydroxy-15-pivaloyl-12-
oxa-1,15-diazatetracyclo[11.3.0.0
2,7
.0
9,13
]heptadeca-2,4,6,10-tetraen-17-one (3.23a) 
and 5-bromo-2-hydroxy-12-pivaloyl-17-oxa-9,12-
diazatetracyclo[11.2.1.0
3,8
.0
5,9
]heptadeca-3,5,7,15-tetraen-10-one (3.24a) in the ratio 
of 1:1.4.  0.26 g of the mixture was then subjected to general procedure SPy using 
pyridine-3-boronic acid (0.086 g, 0.70 mmol), Pd2(dba)3 (0.0063 g, 0.0069 mmol), PCy3 
(0.0046 g, 0.016 mmol), dioxane (2.0 mL), and aqueous K3PO4 (1.1 mmol, 0.84 mL of a 
1.27 M solution) resulting in an isolated yield of 0.050 g (19%) of 8-hydroxy-5-
(pyridin-3-yl)-15-pivaloyl-12-oxa-1,15-diazatetracyclo[11.3.0.0
2,7
.0
9,13
]heptadeca-
2,4,6,10-tetraen-17-one (3.23b) and 0.030 g (12%) of  the title compound. 
1
H NMR (500 
MHz, CDCl3) δ 8.79 (s, 1H), 8.61 (s, 1H), 7.86 (ddd, J = 8.0, 2.4, 1.5 Hz, 1H), 7.52 (dd, J 
= 8.3, 2.2 Hz, 1H), 7.43 (d, J = 2.2 Hz, 1H), 7.38 (m, 2H), 6.31 (dd, J = 6.0, 1.8 Hz, 1H), 
5.75 (dd, J = 5.9, 1.0 Hz, 1H), 5.16 (m, 1H), 4.92 (dd, J = 18.2, 1.6 Hz, 1H), 4.76 (d, J = 
3.6 Hz, 1H), 4.68 (dd, J = 14.0, 1.6 Hz, 1H), 4.26 (d, J = 18.4 Hz, 1H), 3.96 (d, J = 14.0 
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Hz, 1H), 3.42 (s, 1H), 1.37 (s, 9H). 
13
C NMR (126 MHz, CDCl3) δ 176.8, 166.1, 148.8, 
148.1, 137.3, 136.3, 135.7, 135.2, 134.3, 134.1, 131.1, 130.3, 128.0, 126.9, 123.6, 96.9, 
83.9, 79.1, 49.9, 49.7, 38.9, 28.3. HRMS (ESI) calcd for C24H26N3O4
+
 (MH
+
) 420.1918, 
found 420.1920. 
 
10-Hydroxy-5-pivaloyl-16-(pyridine-3-yl)-20-oxa-2,5-
diazapentacyclo [9.7.1.1
7,10
.0
2,7
.0
15,19
]icosa-
1(19),8,15(16),17(18)tetraen-3,5-dione:  General 
procedure I was performed using 0.43 g (0.93 mmol) of N-
(2-(4-bromo-8-oxo-5,6,7,8-tetrahydronaphthalen-1-
ylamino)-2-oxoethyl)-N-(furan-2-ylmethyl)pivalamide (3.15) yielding a mixture 
containing 12-hydroxy-17-bromo-6-pivaloyl-8-oxa-2,5-
diazapentacyclo[10.7.1.0
2,7
.0
7,11
.0
16,20
]icosa-1(20),9,16(17),18-tetraen-3,6-dione (25a) 
and 10-hydroxy-5-pivaloyl-16-bromo-20-oxa-2,5-diazapentacyclo 
[9.7.1.1
7,10
.0
2,7
.0
15,19
]icosa-1(19),8,15(16),17(18)tetraen-3,5-dione (3.26a) in the ratio of 
1:1.5.  0.43 g of the mixture was then subjected to general procedure SPy using pyridine-
3-boronic acid (0.21 g, 1.7 mmol), Pd2(dba)3 (0.020 g, 0.022 mmol), PCy3 (0.015 g, 
0.053 mmol), dioxane (3 mL), and aqueous K3PO4 (2.7 mmol, 2.1 mL of a 1.27 M 
solution) resulting in an isolated yield of 0.086 g, (20%) of the title compound.  
1
H NMR 
(500 MHz, CDCl3) δ 8.62 (d, J = 3.8 Hz, 1H), 8.54 (s, 1H), 7.62 (dt, J = 7.9, 1.9 Hz, 1H), 
7.37 (dd, J = 7.8, 4.8 Hz, 1H), 7.09 (m, 2H), 6.36 (dd, J = 5.9, 1.8 Hz, 1H), 5.80 (dd, J = 
5.9, 0.9 Hz, 1H), 4.97 (d, J = 18.5 Hz, 1H), 4.73 (m, 2H), 4.30 (d, J = 18.3 Hz, 1H), 3.93 
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(d, J = 13.9 Hz, 1H), 3.48 (s, 1H), 2.59 (m, 1H), 2.47 (ddd, J = 17.4, 12.6, 5.5 Hz, 1H), 
2.10 (m, 1H), 1.96 (m, 1H), 1.76 (m, 1H), 1.60 (dt, J = 13.5, 2.9 Hz, 1H), 1.39 (s, 9H).  
13
C NMR (126 MHz, CDCl3) δ 176.8, 166.2, 149.8, 148.4, 138.4, 137.1, 136.9, 136.5, 
136.2, 135.6, 135.2, 129.2, 128.6, 128.2, 123.2, 96.3, 88.4, 75.3, 49.9, 49.1, 38.9, 36.2, 
30.4, 28.3, 17.8.  HRMS (ESI) calcd for C27H30N3O4
+
 (MH
+
) 460.2231, found 460.2234. 
 
10-Hydroxy-5-benzyl-16-(pyridine-3-yl)-20-oxa-2,5-
diazapentacyclo [9.7.1.1
7,10
.0
2,7
.0
15,19
]icosa-
1(19),8,15(16),17(18)tetraen-3,5-dione (3.28b): General 
procedure I was followed using 0.81 g (1.7 mmol) of N-
benzyl-N-(2-(4-bromo-8-oxo-5,6,7,8-
tetrahydronaphthalen-1-yl- amino)-2-oxoethyl)furan-2-carboxamide (3.16) forming 
mixture of 12-hydroxy-17-bromo-6-benzyl-8-oxa-2,5-diazapentacyclo 
[10.7.1.0
2,7
.0
7,11
.0
16,20
]icosa-1(20),9,16(17),18-tetraen-3,6-dione (3.27a) and 10-
hydroxy-5-benzyl-16-bromo-20-oxa-2,5-diazapentacyclo[9.7.1.1
7,10
.0
2,7
.0
15,19
]icosa-
1(19),8,15(16),17(18)tetraen-3,5-dione (3.28a)  in the ratio of 1:16. 0.20 g of the crude 
photoproduct was then subjected to general procedure SPy  using pyridine-3-boronic acid 
(0.081 g, 0.66 mmol), Pd2(dba)3 (0.0090 g, 0.022 mmol), PCy3 (0.0066 g, 0.024 mmol), 
dioxane (1.2 mL), and aqueous K3PO4 (0.42 mmol, 0.56 mL of a 1.27 M solution) 
resulting in an isolated yield of 0.072 g, (36%) of the title compound.  
1
H NMR (500 
MHz, CDCl3) δ 8.62 (dd, J = 5.0, 1.7 Hz, 1H), 8.51 (m, 1H), 7.62 (dt, J = 7.8, 2.0 Hz, 
1H), 7.40 (m, 6H), 7.13 (d, J = 8.0 Hz, 1H), 7.04 (d, J = 7.9 Hz, 1H), 6.40 (dd, J = 6.0, 
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1.8 Hz, 1H), 6.10 (d, J = 5.9 Hz, 1H), 4.96 (d, J = 14.5 Hz, 1H), 4.87 (m, 1H), 4.57 (d, J 
= 14.5 Hz, 1H), 4.40 (d, J = 18.2 Hz, 1H), 4.11 (d, J = 18.2 Hz, 1H), 3.16 (s, 1H), 2.59 
(m, 1H), 2.47 (ddd, J = 17.5, 12.6, 5.4 Hz, 1H), 2.11 (m, 1H), 1.96 (qdd, J = 13.2, 4.9, 2.5 
Hz, 1H), 1.79 (m, 1H), 1.64 (td, J = 13.4, 3.0 Hz, 1H). 
13
C NMR (126 MHz, CDCl3) δ 
167.1, 162.5, 149.8, 148.6, 139.2, 136.9, 136.8, 136.4, 136.1, 135.8, 135.7, 134.6, 129.8, 
129.1, 128.5, 128.5, 128.5, 128.4, 123.1, 96.5, 89.6, 75.8, 49.9, 49.8, 36.3, 30.2, 17.7.  
HRMS (ESI) calcd for C29H26N3O4
+
 (MH
+
) 480.1918, found 480.1927. 
 
8-Hydroxy-5-(thiophen-2-yl)-12-oxa-1-
azatetracyclo[11.3.0.0
2,7
.0
9,13
] hexadeca-2,4,6,10-tetraen-12-
one (4h): N-(2-Formyl-4-iodophenyl)-3-(furan-2-
yl)propanamide (3.3d) (0.42 g, 1.1 mmol) was irradiated 
following the general procedure for irradiation yielding 0.42 g of a mixture of 8-
hydroxy-5-iodo-2-yl-12-oxa-1-azatetracyclo[11.3.0.0
2,7
.0
9,13
]hexadeca-2,4,6,10-
tetraen-12-one (4d) and 2-hydroxy-5-iodo-16-oxa-9-
azatetracyclo[11.2.1.0
3,8
.0
5,9
]hexadeca-3,5,7,14-tetraen-10-one (3.5d)  in the ratio 1:1 
which was used without further purification. Following the general procedure for Suzuki 
coupling STF from 0.20 g (0.54 mmol) of the photoproducts, Pd(PPh3)4 (0.032 g, 0.028 
mmol), thiophene-2-boronic acid (0.077 g, 0.60 mmol), NaHCO3 (0.095 g, 1.1 mmol) in 
H2O (16 mL) upon flash chromatography 0.030 g (17%) of the title compound and  0.044 
g (26%) of 2-hydroxy-5-(thiophen-2-yl)-16-oxa-9-
azatetracyclo[11.2.1.0
3,8
.0
5,9
]hexadeca-3,5,7,14-tetraen-10-one (3.5h) was isolated.
1
H 
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NMR (500 MHz, CDCl3) δ 7.95 (d, J = 8.3 Hz, 1H), 7.66 (dd, J = 8.3, 2.2 Hz, 1H), 7.48 
(d, J = 2.2 Hz, 1H), 7.31 (s, 1H), 7.30 (m, 1H), 7.10 (dd, J = 5.0, 3.7 Hz, 1H), 6.28 (t, J = 
2.8 Hz, 1H), 4.83 (t, J = 2.5 Hz, 1H), 4.70 (dd, J = 3.1, 2.2 Hz, 1H), 3.89 (q, J = 2.3 Hz, 
1H), 2.88 (ddd, J = 16.6, 10.6, 8.2 Hz, 1H), 2.60 (m, 1H), 2.54 (dd, J = 16.5, 8.9 Hz, 1H), 
2.45 (ddd, J = 12.7, 10.6, 8.9 Hz, 1H), 1.90 (m, 1H).  
13
C NMR (126 MHz, CDCl3) δ 
173.2, 146.7, 143.3, 133.4, 132.0, 131.3, 128.1, 127.0, 126.2, 125.0, 123.6, 123.3, 101.3, 
99.3, 70.4, 55.9, 35.1, 29.8. HRMS (ESI) calcd for C18H15LiNO3S
+
 (MLi
+
) 332.0927, 
found 332.0935. 
 
2-Hydroxy-5-(thiophen-2-yl)-16-oxa-9-
azatetracyclo[11.2.1.0
3,8
.0
5,9
]hexadeca-3,5,7,14-tetraen-10-one 
(3.5h): N-(2-Formyl-4-iodophenyl)-3-(furan-2-yl)propan-amide 
(3.3d) (0.42 g, 1.1 mmol) was irradiated following the general 
procedure for irradiation yielding 0.42 g of a mixture containing 8-hydroxy-5-iodo-12-
oxa-1-azatetracyclo[11.3.0.0
2,7
.0
9,13
]hexadeca-2,4,6,10-tetraen-12-one (3.4d) and 2-
hydroxy-5-iodo-16-oxa-9-azatetracyclo[11.2.1.0
3,8
.0
5,9
]hexadeca-3,5,7,14-tetraen-10-
one (3.5d)  in the ratio 1:1 which was used without further purification.  Following the 
general procedure for Suzuki coupling STF from 0.20 g (0.54 mmol) of the 
photoproducts, Pd(PPh3)4 (0.032 g, 0.028 mmol), thiophene-2-boronic acid (0.077 g, 0.60 
mmol), NaHCO3 (0.095 g, 1.1 mmol) in H2O (16 mL) upon flash chromatography 0.030g 
(17%) of 8-hydroxy-5-(thiophen-2-yl)-12-oxa-1-
azatetracyclo[11.3.0.0
2,7
.0
9,13
]hexadeca-2,4,6,10-tetraen-12-one (3.4h) and 0.044 g 
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(26%) of the title compound was isolated. 
1
H NMR (500 MHz, CDCl3) δ 7.60 (dd, J = 
8.4, 2.2 Hz, 1H), 7.55 (m, 2H), 7.31 (m, 2H), 7.10 (dd, J = 5.1, 3.6 Hz, 1H), 6.36 (dd, J = 
5.8, 1.9 Hz, 1H), 5.70 (dd, J = 5.9, 1.1 Hz, 1H), 5.07 (m, 1H), 4.72 (dd, J = 10.8, 3.3 Hz, 
1H), 2.93 (m, 2H), 2.69 (ddd, J = 17.4, 9.8, 1.9 Hz, 1H), 2.58 (m, 1H), 2.49 (ddd, J = 
13.9, 9.5, 1.9 Hz, 1H). 
13
C NMR (126 MHz, CDCl3) δ 173.1, 143.0, 134.7, 133.6, 132.9, 
131.9, 131.6, 129.9, 129.3, 128.1, 126.0, 125.2, 123.4, 103.6, 83.6, 79.3, 30.1, 28.9.  
HRMS (ESI) calcd for C18H15LiNO3S
+
 (MLi
+
) 332.0927, found 332.0931. 
 
5-(Furan-2-yl)-8-hydroxy-12-oxa-1-
azatetracyclo[11.3.0.0
2,7
.0
9,13
]hexadeca-2,4,6,10-tetraen-12-
one (3.4g): N-(2-Formyl-4-iodophenyl)-3-(furan-2-
yl)propanamide (3.3d) (0.31 g, 0.84 mmol) was irradiated 
following the general procedure for irradiation yielding 0.31 g of a mixture containing 8-
hydroxy-5-iodo-12-oxa-1-azatetracyclo[11.3.0.0
2,7
.0
9,13
]hexadeca-2,4,6,10-tetraen-12-
one (3.4d) and 2-hydroxy-5-iodo-16-oxa-9-azatetracyclo[11.2.1.0
3,8
.0
5,9
]hexadeca-
3,5,7,14-tetraen-10-one (3.5d) in the ratio of 2.9:1 which was used without further 
purification. From 0.31 g  (0.83 mmol) of that mixture following the general procedure 
for Suzuki coupling STF, using Pd(PPh3)4 (0.056 g, 0.048 mmol), furan-2-boronic acid 
(0.11 g, 0.98 mmol), NaHCO3 (0.16 g, 1.9 mmol) in water (27 mL) upon flash 
chromatography 0.068 g (27%) of the title compound and 0.10 g (39%) of an inseparable 
mixture of 5-(furan-2-yl)-2-hydroxy-16-oxa-9-azatetracyclo[11.2.1.0
3,8
.0
5,9
]hexadeca-
3,5,7,14-tetraen-10-one (5g) and 4-(furan-2-yl)-15-hydroxy-16-oxa-8-
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azatetracyclo[10.3.1.0
2,7
.0
8,12
]hexadeca-2,4,6,13-tetraen-9-one (3.29) was isolated. 
1
H 
NMR (500 MHz, CDCl3) δ 7.94 (d, J = 8.4 Hz, 1H), 7.70 (dd, J = 8.4, 2.0 Hz, 1H), 7.57 
(d, J = 2.0 Hz, 1H), 7.48 (dd, J = 1.8, 0.7 Hz, 1H), 6.66 (dd, J = 3.3, 0.8 Hz, 1H), 6.50 
(dd, J = 3.4, 1.8 Hz, 1H), 6.26 (t, J = 2.8 Hz, 1H), 4.83 (d, J = 2.2 Hz, 1H), 4.68 (dd, J = 
3.0, 2.2 Hz, 1H), 3.88 (m, 1H), 2.87 (ddd, J = 16.3, 10.4, 8.2 Hz, 1H), 2.52 (m, 4H).  
13
C 
NMR (126 MHz, CDCl3) δ 173.2, 153.1, 146.7, 142.2, 133.2, 131.2, 128.5, 125.0, 124.0, 
123.5, 111.8, 105.2, 101.4, 99.3, 70.4, 55.9, 35.1, 29.8. HRMS (ESI) calcd for 
C18H16NO4
+
 (MH
+
) 310.1074, found 310.1081. 
 
4-(Furan-2-yl)-15-hydroxy-16-oxa-8-
azatetracyclo[10.3.1.0
2,7
.0
8,12
] hexadeca-2,4,6,13-tetraen-9-
one (3.29):  N-(2-Formyl-4-iodophenyl)-3-(furan-2-
yl)propanamide (3.3d) (0.31 g, 0.84 mmol) was irradiated 
following the general procedure for irradiation yielding 0.31 g of a mixture containing 8-
hydroxy-5-iodo-12-oxa-1-azatetracyclo[11.3.0.0
2,7
.0
9,13
]hexadeca-2,4,6,10-tetraen-12-
one (4d) and 2-hydroxy-5-iodo-16-oxa-9-azatetracyclo[11.2.1.0
3,8
.0
5,9
]hexadeca-
3,5,7,14-tetraen-10-one (3.5d) in the ratio of 2.9:1 which was used without further 
purification. From 0.31 g  (0.83 mmol) of that mixture following the general procedure 
for Suzuki coupling, using Pd(PPh3)4 (0.056 g, 0.048 mmol), furan-2-boronic acid (0.11 
g, 0.98 mmol), NaHCO3 (0.16 g, 1.9 mmol) in water (27 mL) upon flash chromatography 
0.068 g (27%) of 5-(furan-2-yl)-8-hydroxy-12-oxa-1-
azatetracyclo[11.3.0.0
2,7
.0
9,13
]hexadeca-2,4,6,10-tetraen-12-one (3.4g) and 0.10 g 
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(39%) of an inseparable mixture of 5-(furan-2-yl)-2-hydroxy-16-oxa-9-
azatetracyclo[11.2.1.0
3,8
.0
5,9
]hexadeca-3,5,7,14-tetraen-10-one (3.5g) and  4-(furan-2-
yl)-15-hydroxy-16-oxa-8-azatetracyclo[10.3.1.0
2,7
.0
8,12
]hexadeca-2,4,6,13-tetraen-9-
one (3.29). A mixture of 5-(furan-2-yl)-2-hydroxy-16-oxa-9-
azatetracyclo[11.2.1.0
3,8
.0
5,9
]hexadeca-3,5,7,14-tetraen-10-one (3.5g) and 4-(furan-2-
yl)-15-hydroxy-16-oxa-8-azatetracyclo[10.3.1.0
2,7
.0
8,12
]hexadeca-2,4,6,13-tetraen-9-
one (3.29) (0.093 g, 0.30 mmol) in 4 nmL of DMSO was placed in a glycerol bath at 160 
°C for 60 min. The solution was allowed to cool, concentrated, and the remaining mixture 
subjected to flash chromatography resulting in an isolated yield of 0.043 g of the title 
compound. 
1
H NMR (500 MHz, CDCl3) δ 8.38 (d, J = 8.7 Hz, 1H), 7.63 (dd, J = 8.6, 2.0 
Hz, 1H), 7.51 (d, J = 2.0 Hz, 1H), 7.48 (dd, J = 1.9, 0.8 Hz, 1H), 6.64 (dd, J = 3.4, 0.8 
Hz, 1H), 6.50 (dd, J = 3.4, 1.8 Hz, 1H), 6.11 (ddd, J = 9.7, 5.3, 1.2 Hz, 1H), 5.86 (m, 
1H), 5.23 (s, 1H), 4.03 (d, J = 5.2 Hz, 1H), 2.74 (m, 2H), 2.40 (m, 2H), 2.28 (s, 1H). 
13
C 
NMR (126 MHz, CDCl3) δ 170.9, 153.1, 142.2, 131.6, 129.5, 127.1, 127.0, 124.1, 123.5, 
120.6, 120.2, 111.8, 105.0, 86.1, 78.1, 66.8, 30.3, 29.9. HRMS (ESI) calcd for 
C18H15LiNO4
+
 (MLi
+
) 316.1156, found 316.1164.  
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X-Ray Structures 
X-Ray structures were obtained with a Bruker APEX II instrument and the structure was refined 
using XShell software.  The goodness of fit “S” is listed after each entry. 
 
1. 8-Hydroxy-5-phenyl-12-oxa-1-azatetracyclo[11.3.0.02,7.09,13]hexadeca-2,4,6,10-
tetraen-16-one (3.4f)  S = 0.891 
 
 
 
 
 
 
 
 
 
2. 11-Hydroxy-16-(pyridine-3-yl)-7-oxa-2-azapentacyclo 
[9.7.1.0
2,6
.0
6,10
.0
15,19
]nonadeca-1(19),8,15(16),17-tetraen-3-one (3.21b) S = 0.907 
 
 
 
 
 
 
 
 
 
 
 
 
  
89 
3. 10-Hydroxy-15-(pyridine-3-yl)-9-oxa-2-
azapentacyclo[8.7.1.1
6,9
.0
2,6
.0
14,18
]nonadeca-1(18),7,14(15),16(17)tetraen-3-one  
(3.22b)  S = 0.747 
 
 
 
 
 
 
 
4. 8-Hydroxy-6-(pyridin-3-yl)-12-oxa-1-azatetracyclo[11.3.0.02,7.09,13] hexadeca-
2,4,6,10-tetraen-16-one (3.17b) S = 1.109 
 
 
 
 
 
 
 
5. 5-(Furan-2-yl)-8-hydroxy-12-oxa-1-azatetracyclo[11.3.0.0
2,7
.0
9,13
]hexadeca-
2,4,6,10-tetraen-12-one (3.4g)  S = 0.876 
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6. 5-(furan-2-yl)-2-hydroxy-16-oxa-9-azatetracyclo[11.2.1.0
3,8
.0
5,9
]hexadeca-
3,5,7,14-tetraen-10-one (3.5g) S = 0.859 
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Chapter 4: o-Azaxylylene Cascade Reactions 
Diversity oriented synthesis aims to probe the greatest region of chemical space 
possible
9
, and this is best accomplished through modifications to the core framework 
which significantly change the overall topology of a molecule.  This chapter focuses on 
the first reported case of o-azaxylylene cascade reactions in the excited state.  Not only 
does this approach yield a significantly unique topology in keeping with DOS, but also 
forms multiple fused sp
3 
ring systems, which can be synthesized in a one-pot two-step 
fashion, from affordable starting materials, and obtained without column 
chromatography.  These products contain many stereogenic centers, have a large fraction 
of sp
3
 carbons, few rotatable bonds, and multiple fused bridges which are all 
characteristics of active pharmaceuticals derived from natural products.
6
 
 
Introduction 
Cascade reactions have been shown to be a prominent method from which nature 
generates this selectivity.
38
  Polycyclic structures with multiple stereocenters generated 
from linear achiral precursors are a stunning example of this phenomena, and is 
demonstrated in the electrophilic cascade leading to the formation of  terpenes,
39
 such as 
the steroid precursor lanosterol illustrated in Figure 4.1.  
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Figure 4.1 
 
  Cascade reactions are often regarded as an “environmentally friendly means to 
generate molecular complexity”40 in the formation of natural or designed products.  
However, implementation of this methodology on the bench top does pose some 
challenges, as cascade reactions by their very nature rely on the formation of highly 
reactive, short-lived intermediates in minute quantities without any spatial 
compartmentalization of sequential processes making the control over the reaction 
difficult, if not impossible.  These reactions are not only attractive from the standpoint of 
synthesizing natural or designed products, but also have the potential to serve as powerful 
tools in the exploration of chemical space. 
Herein we set out to utilize two photochemically generated o-azaxylylene 
intermediates, resulting from the excited state intramolecular proton transfer of o-amido 
aldehydes and ketones, in a cascade reaction that results in a rapid growth in complexity 
to yield novel fused ring systems.  
 
Results and Discussion 
Photoprecursors were equipped with two reactive o-acylanilid moieties, each of 
which can form o-azaxylylenes upon irradiation and potentially react with a dieneophile.  
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The system was designed so that the first o-azaxylylene addition to the tethered furan 
pendant would bring the second tethered o-azaxylylene into close spatial proximity so 
that it could react with the newly formed 2,5- or 3,4-dihydrofuran moiety generated from 
the first addition (Scheme 4.1) 
 
 
Scheme 4.1 
 
 In order to introduce two azaxylylene pendants into one framework, a two-step 
one-pot procedure was developed (Scheme 4.2):  (i) acetylation of isatin (4.1) with 
furanpropanoic acids 4.2 or 4.3 followed by (ii) ring opening with anilines 4.6a-d.  
Photoprecursors 4.7b-d were obtained after workup, while photoprecursors 4.7a and 4.8a 
required an additional oxidation step with PCC to yield the aldehyde products. 
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Scheme 4.2 
 
Photoprecursors (4.7a-d, 4.8a) are characterized by the maximum UV absorption 
between 350-365 nm, and were irradiated using a Rayonet broadband 300-400 nm UV 
source yielding photoproducts 4.9-14 in moderate to good yields.  The reaction was 
found to be substantially slower for photoprecursors bearing one reactive o-azaxylylene 
core
21
, with an absolute quantum yield of cyclization for the irradiation of 4.7b being < 
0.02. 
Irradiation of photoprecursors 4.7a-d yielded three products (Scheme 4.3): (i) [4 
+ 4] or “single click” cyclization products 4.9a-d, (ii) [4 + 2]/[4 + 2] or “double click” 
cascade products 4.10a-d, and (iii) [4 + 2]/disproportion or “1.5 click” cascade products 
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4.11a-d.  Irradiation of photoprecursor 4.8a yielded only the single click [4 + 4] (4.12) 
and [4 + 2]/[4 + 2] double click (4.13) products.  The photoproduct of [4 + 4] cyclization 
likely does not undergo a cascade reaction because of the unfavorable spatial 
arrangement between the o-azaxylyene core and the double bond resulting from the initial 
cycloaddition.    
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Scheme 4.3 
 
It is likely that the double click and disproportionation products are derived from 
an initial [4 + 2] cyclization.  When monitoring the reaction by 
1
H NMR, the 
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accumulation and subsequent disappearance of a single click [4 + 2] cyclization is 
observed, and this disappearance is likely the result of the [4 + 2] cycloaddition product 
being consumed through the double click and disproportionation channels.  Given these 
observations and the previous work on the mechanism of o-azaxylylene cycloaddition
21
, 
the double click and disproportionation process is postulated to proceed through 
excitation to S1, followed by excited state intramolecular proton transfer, intersystem 
crossing to the triplet state, and a step-wise addition to the furan pendant starting with the 
N-centered attack and finishing with radical recombination to reach the single click [4 + 
2] product.  At this point, the same process occurs with the second pendant; however, 
after the initial attack on the double bond the second radical can do one of two things: (a) 
radical recombination forming the double click product, or (b) hydrogen abstraction from 
the OH group reforming the o-amido ketone or aldehyde leading to the 1.5 click product 
(Scheme 4.4).  
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Scheme 4.4 
 
In all cases only one diastereomer was observed, and the stereochemistry was 
assigned using NOE experiments (Figure 4.2).  For compound 4.10b irradiation of the 
methyl group results in the enhancement of Hb (2.2%) and Ha (0.8%) signals.  Irradiation 
of OH-b does not result in the enhancement of any proton signals, and the irradiation of 
OH-a results in the enhancement of Hc (3%).  This suggests that Ha, Hb, and Hc, and 
OH-a are on the same face.  Compound 4.11b showed signal enhancement of He (12%) 
upon irradiation of Hd, implying that these protons are on the same face.  The 
1
NMR 
spectra are in agreement with calculations using a relativistic force field method 
developed by Kutateladze et al.
41
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Figure 4.2 
 
Experimental 
Common solvents were purchased from Pharmco and used as is, except for THF, 
which was refluxed over and distilled from potassium benzophenone ketyl prior to use. 
Common reagents were purchased from Aldrich or TCI America and used without 
additional purification, unless indicated otherwise. NMR spectra were recorded at 25
°
C 
on a Bruker Avance III 500 MHz in CDCl3 with TMS as an internal standard (unless 
noted otherwise). High resolution mass spectra were obtained on the MDS 
SCIEX/Applied Biosystems API QSTARTM Pulsar i Hybrid LC/MS/MS System mass 
spectrometer by Dr. Jeremy Balsbaugh at the University of Colorado at Boulder.  Flash 
column chromatography was performed using Teledyne Ultra Pure Silica Gel (230 – 400 
mesh) on a Teledyne Isco Combiflash Rf using Hexanes/EtOAc or DCM/Methanol as 
eluents. 8-Amino-1-tetralone
42
 and 1-(2-amino-5-bromophenyl)ethanone
36
 were 
synthesized according to the published procedures. 
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Synthesis of photoprecursors 
 
General procedure for isatin coupling (A): Isatin (1 mmol) was added to the 
solution of carboxylic acid (1.2 mmol) in DCM (4 mL) at 0 °C, followed by EDC (1.2 
mmol) and DMAP (0.10 mmol).  The reaction mixture was allowed to stir at room 
temperature for three hours, followed by the addition of the amine (1.2 mmol) and left 
stirring overnight.  The mixture was diluted with DCM (14 mL), and washed with 5% aq. 
HCl, water, a solution of sat. aq. NaHCO3, and water (6 mL each).  The organic layer was 
dried over anh. Na2SO4, filtered, concentrated, and purified by flash chromatography 
(Hex/EtOAc) yielding the desired product. 
 
General procedure for the oxidation of alcohols to aldehydes (B): To a stirred 
mixture of the alcohol (1 mmol) in dry DCM (8 mL) was added PCC (1.6 mmol).  The 
reaction mixture was left stirring overnight, filtered through a layer of silica gel using 
CH2Cl2/3% MeOH, (100 mL) as an eluent, concentrated, and purified by flash 
chromatography (Hex/EtOAc) yielding the isolated desired product. 
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N-(2-(((2-Formylphenyl)carbamoyl]carbonyl)phenyl)-3-
(furan-2-yl)propanamide (4.7a) : Following general procedure 
A,  from furanpropanoic acid (0.34 g, 2.4 mmol), isatin (0.30 g, 
2.0 mmol), EDC (0.47 g, 2.5 mmol), DMAP (0.025 g, 0.20 
mmol), and 2-aminobenzyl alcohol (0.30 g, 2.4 mmol) in DCM 
(12 mL) upon workup 3-(furan-2-yl)-N-[2-(((2-
(hydroxymethyl)phenyl)carbamoyl)carbonyl)phenyl)propanamide  (0.78 g, crude) 
was obtained, and used in the next step without further purification. 
1
H NMR (500 MHz, 
CDCl3) δ 11.01 (s, 1H), 10.12 (s, 1H), 8.74 (dd, J = 8.6, 1.2 Hz, 1H), 8.54 (dd, J = 8.1, 
1.5 Hz, 1H), 8.32 (dd, J = 8.1, 1.1 Hz, 1H), 7.67 (ddd, J = 8.8, 7.5, 1.6 Hz, 1H), 7.45 (td, 
J = 7.8, 1.6 Hz, 1H), 7.34 (dd, J = 1.9, 0.9 Hz, 1H), 7.27 (d, J = 1.4 Hz, 1H), 7.20 (m, 
2H), 6.30 (dd, J = 3.2, 1.9 Hz, 1H), 6.10 (dd, J = 3.3, 0.8 Hz, 1H), 4.86 (d, J = 5.5 Hz, 
2H), 3.12 (t, J = 7.6 Hz, 2H), 2.84 (dd, J = 7.8, 6.4 Hz, 2H), 2.28 (t, J = 5.6 Hz, 1H)  
General procedure B was followed using 3-(furan-2-yl)-N-[2-(((2-
(hydroxymethyl)phenyl)carbamoyl)carbonyl)phenyl)propanamide (0.78 g), and PCC 
(0.64 g, 3.0 mmol) in DCM (50 mL).  Upon purification by flash chromatography 0.31 g 
(40% over two steps) of the title compound was isolated.
 1
H NMR (500 MHz, CDCl3) δ 
12.35 (s, 1H), 11.06 (s, 1H), 10.05 (d, J = 0.8 Hz, 1H), 8.87 (d, J = 8.4 Hz, 1H), 8.79 (dd, 
J = 8.6, 1.1 Hz, 1H), 8.45 (dd, J = 8.1, 1.6 Hz, 1H), 7.82 (dd, J = 7.6, 1.7 Hz, 1H), 7.74 
(m, 1H), 7.68 (ddd, J = 8.8, 7.2, 1.6 Hz, 1H), 7.41 (td, J = 7.5, 1.0 Hz, 1H), 7.36 (dd, J = 
1.9, 0.9 Hz, 1H), 7.19 (ddd, J = 8.2, 7.3, 1.2 Hz, 1H), 6.30 (dd, J = 3.2, 1.9 Hz, 1H), 6.12 
(m, 1H), 3.14 (t, J = 7.6 Hz, 2H), 2.88 (dd, J = 8.3, 6.8 Hz, 2H). 
 13
C NMR (126 MHz, 
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CDCl3) δ 195.2, 190.4, 171.0, 161.3, 153.9, 142.5, 141.3, 139.2, 136.8, 136.2, 136.1, 
134.3, 124.4, 122.8, 122.5, 121.0, 120.3, 118.4, 110.2, 105.6, 36.8, 23.7. HRMS (ESI) 
calcd for C22H19BrN2O5
+
 (MH
+
) 391.1288, found 391.1299. 
 
N-(2-(((2-Formylphenyl)carbamoyl)carbonyl)phenyl)-
3-(5-(2-(trifluoromethyl)phenyl)furan-2-
yl)propanamide (4.8a): Following general procedure A,  
from 3-(5-(2-(trifluoromethyl)phenyl)furan-2-
yl)propionic acid (0.90 g, 3.2 mmol), isatin (0.39 g, 2.7 
mmol), EDC (0.61 g, 3.2 mmol), DMAP (0.032 g, 0.26 mmol), and 2-aminobenzyl 
alcohol (0.39 g, 3.2 mmol) in DCM (40 mL) N-(2-(((2-
(hydroxymethyl)phenyl)carbamoyl)carbonyl)phenyl)-3-(5-(2-
(trifluoromethyl)phenyl)furan-2-yl)propanamide  
 (1.72 g, crude) was obtained, and used in the next step without further 
purification.  
1
H NMR (500 MHz, CDCl3) δ 11.06 (s, 1H), 10.15 (s, 1H), 8.75 (dd, J = 
8.5, 1.1 Hz, 1H), 8.53 (dd, J = 8.2, 1.6 Hz, 1H), 8.30 (dd, J = 8.2, 1.2 Hz, 1H), 7.73 (m, 
2H), 7.67 (ddd, J = 8.8, 7.3, 1.6 Hz, 1H), 7.53 (m, 1H), 7.43 (td, J = 8.0, 1.5 Hz, 1H), 
7.38 (m, 1H), 7.26 (dd, J = 8.2, 1.2 Hz, 1H), 7.20 (m, 2H), 6.64 (d, J = 3.4 Hz, 1H), 6.23 
(d, J = 3.4 Hz, 1H), 4.83 (s, 2H), 3.20 (t, J = 7.5 Hz, 2H), 2.90 (dd, J = 8.4, 6.8 Hz, 2H).  
General procedure B was followed using N-(2-(((2-
(hydroxymethyl)phenyl)carbamoyl)carbonyl)phenyl)-3-(5-(2-
(trifluoromethyl)phenyl)furan-2-yl)propanamide (1.72 g), and PCC (1.04 g, 4.82 
  
103 
mmol) in DCM (50 mL).  Upon purification by flash chromatography 0.36 g (25 % over 
two steps) of the title compound was obtained.  
1
H NMR (500 MHz, CDCl3) δ 12.33 (s, 
1H), 11.10 (s, 1H), 10.03 (d, J = 0.7 Hz, 1H), 8.86 (d, J = 8.4 Hz, 1H), 8.79 (dd, J = 8.7, 
1.1 Hz, 1H), 8.45 (dd, J = 8.1, 1.6 Hz, 1H), 7.81 (dd, J = 7.6, 1.6 Hz, 1H), 7.74 (m, 3H), 
7.68 (ddd, J = 8.7, 7.4, 1.6 Hz, 1H), 7.54 (m, 1H), 7.40 (td, J = 7.5, 1.0 Hz, 1H), 7.37 (m, 
1H), 7.20 (ddd, J = 8.2, 7.3, 1.2 Hz, 1H), 6.65 (d, J = 3.3 Hz, 1H), 6.25 (dt, J = 3.3, 0.9 
Hz, 1H), 3.22 (t, J = 7.5 Hz, 2H), 2.94 (dd, J = 8.3, 6.8 Hz, 2H).
 13
C NMR (126 MHz, 
CDCl3) δ 195.2, 190.4, 170.9, 161.2, 154.7, 149.2, 142.4, 139.2, 136.8, 136.2, 136.1, 
134.3, 131.6, 129.8 (q, J = 1.9 Hz, 1C), 129.5, 127.2, 126.6 (q, J = 6.0 Hz, 1C), 126.0 (q, 
J = 31.2 Hz, 1C), 124.5, 124.1 (q, J = 273.8 Hz, 1C), 122.8, 122.5, 121.1, 120.2, 118.4, 
111.0(q, J = 3.6 Hz, 1C), 108.0, 36.6, 23.8.  HRMS (ESI) calcd for C29H22F3N2O5
+
 
(MH
+
) 535.1475, found 535.1496. 
 
N-(2-(((2-Acetylphenyl)carbamoyl)carbonyl)phenyl)-3-
(furan-2-yl)propanamide (4.7b): Following general procedure 
A,  from furanpropanoic acid (1.71 g, 12.2 mmol), isatin (1.50 g, 
12.2 mmol), EDC (2.35 g, 12.3 mmol), DMAP (0.12 g, 0.98 
mmol), and 2’-aminoacetophenone (1.65 g, 12.2 mmol) in DCM 
(45 mL) upon purification by flash chromatography 2.08 g (50 %) of the title compound 
was isolated. 
 1
H NMR (500 MHz, CDCl3) δ 12.93 (s, 1H), 11.10 (s, 1H), 8.87 (dd, J = 
8.4, 1.2 Hz, 1H), 8.78 (dd, J = 8.5, 1.2 Hz, 1H), 8.43 (dd, J = 8.1, 1.6 Hz, 1H), 8.02 (dd, J 
= 8.0, 1.6 Hz, 1H), 7.67 (m, 2H), 7.35 (dd, J = 1.9, 0.9 Hz, 1H), 7.29 (m, 1H), 7.18 (ddd, 
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J = 8.3, 7.2, 1.2 Hz, 1H), 6.30 (dd, J = 3.2, 1.8 Hz, 1H), 6.10 (m, 1H), 3.13 (t, J = 7.5 Hz, 
2H), 2.86 (dd, J = 8.4, 6.6 Hz, 2H), 2.74 (s, 3H). 
 13
C NMR (126 MHz, CDCl3) δ 202.8, 
191.0, 171.0, 161.4, 154.0, 142.4, 141.3, 139.4, 136.7, 135.2, 134.3, 131.9, 123.9, 122.9, 
122.5, 121.0, 121.0, 118.4, 110.2, 105.6, 36.7, 28.5, 23.7. HRMS (ESI) calcd for 
C23H21N2O5
+
 (MH
+
) 405.1445, found 405.1454. 
 
N-(2-(((2-Acetyl-4-
bromophenyl)carbamoyl)carbonyl)phenyl)-3-(furan-2-
yl)propanamide (4.7c): Following general procedure A,  from 
furanpropanoic acid (1.14 g, 8.13 mmol), isatin (1.00 g, 6.80 
mmol), EDC (1.56 g, 8.14 mmol), DMAP (0.083 g, 0.68 mmol), 
and 1-(2-amino-5-bromophenyl)ethanone (1.75 g, 8.18 mmol) in DCM (30 mL) upon 
purification by flash chromatography 0.81 g (25 %) of the title compound was isolated.  
1
H NMR (500 MHz, CDCl3) δ 12.83 (s, 1H), 11.05 (s, 1H), 8.81 (d, J = 9.0 Hz, 1H), 8.78 
(dd, J = 8.6, 1.1 Hz, 1H), 8.43 (dd, J = 8.1, 1.6 Hz, 1H), 8.11 (d, J = 2.3 Hz, 1H), 7.77 
(dd, J = 8.9, 2.3 Hz, 1H), 7.67 (ddd, J = 8.7, 7.2, 1.7 Hz, 1H), 7.35 (dd, J = 1.9, 0.9 Hz, 
1H), 7.19 (ddd, J = 8.2, 7.2, 1.2 Hz, 1H), 6.30 (dd, J = 3.2, 1.9 Hz, 1H), 6.11 (m, 1H), 
3.13 (t, J = 7.5 Hz, 2H), 2.86 (dd, J = 8.3, 6.8 Hz, 2H), 2.74 (s, 3H).
  13
C NMR (126 
MHz, CDCl3) δ 201.6, 190.5, 171.0, 161.2, 153.9, 142.5, 141.3, 138.3, 137.8, 136.8, 
134.5, 134.3, 124.3, 122.6, 122.5, 121.0, 118.3, 116.5, 110.2, 105.6, 36.7, 28.6, 23.7. 
HRMS (ESI) calcd for C23H20BrN2O5
+
 (MH
+
) 483.0550, found 483.0557. 
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3-(Furan-2-yl)-N-(2-(((8-oxo-5,6,7,8-tetrahydronaphthalen-1-
yl)carbamoyl)carbonyl)phenyl)propanamide (4.7d): Following 
general procedure A,  from furanpropanoic acid (0.62 g, 4.4 
mmol), isatin (0.55 g, 3.7 mmol), EDC (0.85 g, 4.4 mmol), 
DMAP (0.045 g, 0.37 mmol), and 8-aminotetralone (0.72 g, 4.5 
mmol) in DCM (50 mL) upon purification by flash chromatography 0.57 g (35%) of the 
title compound was isolated.
  1
H NMR (500 MHz, CDCl3) δ 13.35 (s, 1H), 11.14 (s, 1H), 
8.79 (dd, J = 8.5, 1.2 Hz, 1H), 8.73 (d, J = 8.4 Hz, 1H), 8.42 (dd, J = 8.1, 1.6 Hz, 1H), 
7.66 (ddd, J = 8.7, 7.3, 1.6 Hz, 1H), 7.57 (d, J = 8.0 Hz, 1H), 7.35 (dd, J = 2.0, 0.9 Hz, 
1H), 7.18 (ddd, J = 8.3, 7.2, 1.2 Hz, 1H), 7.10 (m, 1H), 6.30 (dd, J = 3.2, 1.9 Hz, 1H), 
6.10 (m, 1H), 3.14 (t, J = 7.6 Hz, 2H), 3.06 (t, J = 6.1 Hz, 2H), 2.86 (dd, J = 8.4, 6.8 Hz, 
2H), 2.78 (dd, J = 7.1, 6.2 Hz, 2H), 2.16 (p, J = 6.4 Hz, 2H). 
 13
C NMR (126 MHz, 
CDCl3) δ 203.4, 191.2, 171.0, 161.5, 154.0, 146.5, 142.4, 141.3, 140.3, 136.6, 135.1, 
134.3, 124.7, 122.4, 120.9, 119.4, 118.6, 118.4, 110.2, 105.5, 40.6, 36.7, 30.9, 23.7, 22.7. 
HRMS (ESI) calcd for C25H23N2O5
+
 (MH
+
) 431.1601, found 431.1612. 
 
Photochemical reactions  
General procedure for irradiation (C): Solutions with ca. 4 mM of the 
photoprecursors in DCM were degassed with N2 and irradiated in Pyrex or borosilicate 
glass reaction vessels in a Rayonet reactor equipped with RPR-3500 UV lamps 
(broadband 300-400 nm UV source with peak emission at 350 nm) until consumption of 
the starting material and [4 + 2] cycloaddition products was observed, as determined by 
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1
H NMR.  Specific purification procedures are listed below the compound of interest.  
When purification by chromatography was necessary compounds were separated using 
silica gel with DCM and MeOH as an eluent. 
 
Irradiation of N-(2-(((2-formylphenyl)carbonyl)phenyl)-3-(furan-2-yl)propanamide 
(4.7a):  General procedure C was followed using 0.28 g of 4.7a (0.72 mmol) in DCM 
(250 mL).  Irradiation of N-(2-(((2-formylphenyl)carbonyl)phenyl)-3-(furan-2-
yl)propanamide (4.7a)The mixture was purified by flash chromatography yielding pure 
14,23-dihydroxy-2-oxa-7,16-
diazaheptacyclo[11.9.2.0
3,7
.0
3,25
.0
8,13
.0
16,24
.0
17,22
]pentacos-17(18),19(20),21(22)-
hexaene-6,15-dione (4.10a) (0.093 g, 33%), 5-(2-formylphenyl)-2-oxa,5,14-diaza-
pentacyclo[10.5.1.0
1,14
.0
4,8
.0
8,13
]octadec-8(9),10(11),12(13)-triene-6,15-dione (4.11a) 
(0.021 g, 8%), and N-(2-formylphenyl)-12-hydroxy-4-oxo-16-oxa-5-
azatetracyclo[11.2.1.0¹,⁵.0⁶,¹¹]hexadeca-6,8,10,14-tetraene-12-carboxamide (4.9a) 
(0.036 g, 13%). 
 
4.10a:
  1
H NMR (500 MHz, CDCl3) δ 8.35 (m, 2H), 7.69 (dd, J 
= 7.9, 1.2 Hz, 1H), 7.50 (td, J = 7.7, 1.5 Hz, 1H), 7.40 (m, 2H), 
7.31 (m, 1H), 7.20 (ddd, J = 8.6, 7.4, 1.3 Hz, 1H), 4.83 (d, J = 
5.6 Hz, 1H), 4.63 (dd, J = 9.0, 6.8 Hz, 1H), 4.40 (dd, J = 6.8, 5.7 
Hz, 1H), 3.48 (d, J = 9.0 Hz, 1H), 3.35 (s, 1H), 2.89 (dt, J = 
17.1, 9.6 Hz, 1H), 2.54 (m, 2H), 2.34 (m, 2H).  
13C NMR (126 MHz, DMSO) δ 174.3, 
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171.2, 136.0, 133.3, 133.2, 129.9, 129.5, 128.8, 128.6, 127.0, 126.3, 124.1, 122.8, 119.2, 
98.9, 74.2, 71.8, 65.0, 61.0, 51.3, 31.8, 30.3.  HRMS (ESI) calcd for C22H19N2O5
+
 (MH
+
) 
391.1288, found 391.1293. 
 
4.11a:  
1
H NMR (500 MHz, CDCl3) δ 9.91 (s, 1H), 8.33 (dd, J = 8.2, 
1.3 Hz, 1H), 8.15 (dd, J = 8.0, 1.6 Hz, 1H), 8.00 (dd, J = 7.7, 1.6 Hz, 
1H), 7.72 (td, J = 7.7, 1.6 Hz, 1H), 7.61 (td, J = 7.6, 1.1 Hz, 1H), 
7.48 (m, 1H), 7.27 (m, 2H), 4.89 (ddd, J = 9.4, 6.0, 3.9 Hz, 1H), 3.88 
(dd, J = 10.3, 6.0 Hz, 1H), 3.78 (dd, J = 10.3, 3.8 Hz, 1H), 3.71 (d, J 
= 9.0 Hz, 1H), 3.43 (s, 1H), 2.83 (dt, J = 17.1, 9.5 Hz, 1H), 2.51 (ddd, J = 17.2, 9.6, 2.2 
Hz, 1H), 2.45 (ddd, J = 13.2, 9.3, 2.3 Hz, 1H), 2.32 (dt, J = 13.2, 9.6 Hz, 1H). 
 13
C NMR 
(126 MHz, CDCl3) δ 189.4, 174.2, 173.0, 137.5, 135.1, 133.6, 132.8, 132.1, 130.3, 128.6, 
127.9, 127.1, 126.6, 125.7, 121.6, 98.3, 71.8, 69.2, 62.8, 54.5, 31.2, 29.7.  HRMS (ESI) 
calcd for C22H19N2O5
+
 (MH
+
) 391.1288, found 391.1301. 
 
4.9a:  
1
H NMR (500 MHz, CDCl3) δ 12.56 (s, 1H), 10.02 (s, 
1H), 8.96 (d, J = 8.4 Hz, 1H), 7.80 (dd, J = 7.7, 1.7 Hz, 1H), 7.72 
(ddd, J = 8.8, 7.7, 1.7), 7.48 (dd, J = 7.8, 1.1 Hz, 1H), 7.37 (m, 
2H), 7.18 (m, 2H), 6.74 (dd, J = 5.8, 2.0 Hz, 1H), 5.72 (dd, J = 
5.8, 1.1 Hz, 1H), 4.90 (dd, J = 2.0, 1.1 Hz, 1H), 4.61 (s, 1H), 
2.85 (dt, J = 17.3, 9.7 Hz, 1H), 2.66 (ddd, J = 17.3, 9.6, 1.6 Hz, 1H), 2.56 (dt, J = 13.9, 
9.9 Hz, 1H), 2.47 (ddd, J = 13.8, 9.4, 1.6 Hz, 1H).  
13
C NMR (126 MHz, CDCl3) δ 194.6, 
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173.2, 171.3, 139.3, 136.9, 136.1, 135.9, 133.8, 133.2, 129.4, 128.7, 128.5, 128.0, 126.8, 
123.9, 123.0, 120.0, 104.1, 85.4, 85.0, 30.0, 28.8. HRMS (ESI) calcd for C22H18LiN2O5
+
 
(MH
+
) 397.1370, found 397.1380. 
 
Irradiation of N-(2-(((2-formylphenyl)carbamoyl)carbonyl)phenyl)-3-(5-(2-
(trifluoromethyl)phenyl)furan-2-yl)propanamide (4.8a):  General procedure C was 
followed using 0.32 g  of 4.8a (0.60 mmol) in DCM (250 mL).  The mixture was purified 
by flash chromatography yielding pure 14,23-Dihydroxy-1-(2-
(trifluoromethyl)phenyl)-2-oxa-7,16-
diazaheptacyclo[11.9.2.0
3,7
.0
3,25
.0
8,13
.0
16,24
.0
17,22
]pentacos-17(18),19(20),21(22)-
hexaene-6,15-dione (4.13) (0.042 g, 13%), and N-(2-formylphenyl)-12-hydroxy-4-oxo-
13-[2-(trifluoromethyl)phenyl]-16-oxa-5-azatetracyclo[11.2.1.0¹,⁵.0⁶,¹¹]hexadeca-
6,8,10,14-tetraene-12-carboxamide (4.12) (0.030 g, 9%). 
 
4.13:  
1
H NMR (500 MHz, DMSO) δ 8.20 (dd, J = 8.0, 1.6 Hz, 
1H), 8.16 (dd, J = 8.3, 1.3 Hz, 1H), 7.88 (dd, J = 7.9, 1.5 Hz, 
1H), 7.55 (dd, J = 7.8, 1.3 Hz, 1H), 7.49 (m, 2H), 7.44 (td, J = 
7.9, 1.2 Hz, 1H), 7.35 (ddd, J = 8.8, 7.3, 1.6 Hz, 1H), 7.16 (td, J 
= 7.5, 1.3 Hz, 1H), 7.12 (ddd, J = 8.5, 7.3, 1.3 Hz, 1H), 7.01 
(dd, J = 7.4, 1.4 Hz, 1H), 6.95 (d, J = 8.0 Hz, 1H), 6.56 (s, 1H), 5.47 (d, J = 9.5 Hz, 1H), 
4.39 (d, J = 2.3 Hz, 1H), 3.86 (d, J = 2.3 Hz, 1H), 3.53 (d, J = 9.3 Hz, 1H), 2.59 (dt, J = 
18.7, 9.5 Hz, 1H), 2.43 (dd, J = 17.2, 9.5 Hz, 1H), 2.22 (dt, J = 13.5, 9.9 Hz, 1H), 1.79 
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(ddd, J = 13.7, 9.7, 1.7 Hz, 1H). 
 13C NMR (126 MHz, DMSO) δ 173.4, 172.6, 141.6, 
137.2, 133.8, 133.0, 132.0, 130.2, 129.9, 129.4, 129.1, 128.9, 128.9, 128.7, 127.4, 125.8, 
124.9, 121.0, 101.7, 88.8, 74.6, 70.8, 66.5, 54.4, 40.1, 32.8, 29.4.  HRMS (ESI) calcd for 
C29H21F3LiN2O5
+
 (MH
+
) 541.1557, found 541.1539.  
 
4.12:  
1H NMR (500 MHz, DMSO) δ 11.82 (s, 1H), 9.70 (s, 1H), 
8.56 (d, J = 8.3 Hz, 1H), 7.85 (dd, J = 7.7, 1.7 Hz, 1H), 7.74 (m, 
3H), 7.48 (dd, J = 8.1, 1.5 Hz, 1H), 7.44 (s, 1H), 7.36 (dd, J = 7.5, 
1.1 Hz, 1H), 7.33 (m, 2H), 7.27 (td, J = 7.8, 1.5 Hz, 1H), 7.15 
(ddd, J = 8.5, 7.0, 1.5 Hz, 1H), 7.11 (dd, J = 8.1, 1.6 Hz, 1H), 7.09 
(d, J = 5.7 Hz, 1H), 5.95 (d, J = 5.7 Hz, 1H), 2.77 (m, 1H), 2.59 (m, 2H), 2.27 (m, 1H).  
13C NMR (126 MHz, DMSO) δ 195.2, 173.0, 172.8, 139.8, 138.5, 137.6, 136.1, 135.8, 
135.0, 134.1, 132.2, 131.4, 130.9, 128.4, 128.1, 127.8, 127.5, 125.9, 124.4, 123.6, 120.3, 
104.1, 95.1, 91.8, 30.4, 28.3.  HRMS (ESI) calcd for C29H21F3LiN2O5
+
 (MH
+
) 541.1557, 
found 541.1578.  
 
Irradiation of N-(2-(((2-acetylphenyl)carbamoyl)carbonyl)phenyl)-3-(furan-2-
yl)propanamide (4.7b): General procedure C was followed using 0.35 g of 4.7b (0.87 
mmol) in DCM (250 mL).  Following the irradiation, the solution was concentrated to 40 
mL, the mixture was centrifuged, the precipitate formed was filtered, washed with cold 
DCM (3 x 10 mL) followed by water (3 x 10 mL), and dried in a desiccator yielding pure 
4,23-dihydroxy-23-methyl -2-oxa-7,16-
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diazaheptacyclo[11.9.2.0
3,7
.0
3,25
.0
8,13
.0
16,24
.0
17,22
]pentacos-17(18),19(20),21(22)-
hexaene-6,15-dione (4.10) (0.12 g, 34%). The filtrate was purified by flash 
chromatography (DCM/MeOH) yielding pure 5-(2-acetylphenyl)-2-oxa,5,14-diaza-
pentacyclo[10.5.1.0
1,14
.0
4,8
.0
8,13
]octadec-8(9),10(11),12(13)-triene-6,15-dione (4.11b) 
(0.049 g, 14%) and N‐(2‐acetylphenyl)‐12‐hydroxy‐4‐oxo‐16‐oxa‐5‐aza-
tetracyclo[11.2.1.0¹,⁵.0⁶,¹¹]hexadeca‐6,8,10,14‐tetraene‐12‐carboxamide (4.9b) (0.084 
g, 24%).   
 
4.10b:  
1H NMR (500 MHz, DMSO) δ 8.29 (dd, J = 8.4, 1.3 Hz, 
1H), 8.12 (dd, J = 8.0, 1.6 Hz, 1H), 7.78 (dd, J = 8.0, 1.3 Hz, 
1H), 7.53 (dd, J = 7.8, 1.5 Hz, 1H), 7.31 (m, 2H), 7.22 (td, J = 
7.5, 1.3 Hz, 1H), 7.14 (td, J = 7.7, 1.3 Hz, 1H), 6.63 (s, 1H), 4.78 
(dd, J = 7.6, 4.5 Hz, 1H), 4.54 (s, 1H), 4.10 (d, J = 4.6 Hz, 1H), 
3.26 (d, J = 7.5 Hz, 1H), 2.77 (dt, J = 16.8, 9.4 Hz, 1H), 2.65 (dd, J = 13.1, 8.4 Hz, 1H), 
2.20 (m, 1H), 1.49 (s, 3H). 
 13C NMR (126 MHz, DMSO) δ 174.6, 171.6, 135.8, 134.9, 
133.3, 129.9, 128.8, 128.1, 126.7, 126.7, 126.0, 124.0, 122.1, 119.0, 98.5, 78.6, 71.9, 
68.2, 60.3, 51.3, 32.1, 30.6, 30.4. HRMS (ESI) calcd for C23H20LiN2O5
+
 (MLi
+
) 
411.1527, found 411.1547.   
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4.11b:  
1
H NMR (500 MHz, CDCl3) δ 8.30 (dd, J = 8.3, 1.2 Hz, 
1H), 8.05 (dd, J = 8.0, 1.5 Hz, 1H), 7.81 (dd, J = 7.7, 1.6 Hz, 1H), 
7.57 (td, J = 7.7, 1.6 Hz, 1H), 7.50 (td, J = 7.6, 1.3 Hz, 1H), 7.45 
(ddd, J = 8.6, 7.5, 1.6 Hz, 1H), 7.22 (td, J = 7.7, 1.3 Hz, 1H), 7.13 
(dd, J = 7.8, 1.3 Hz, 1H), 4.84 (dt, J = 9.1, 5.3 Hz, 1H), 3.91 (m, 
2H), 3.69 (d, J = 9.2 Hz, 1H), 3.49 (s, 1H), 2.81 (dt, J = 17.1, 9.4 Hz, 1H), 2.62 (s, 3H), 
2.44 (m, 2H), 2.32 (dt, J = 13.2, 9.7 Hz, 1H). 
 13
C NMR (126 MHz, CDCl3) δ 199.7, 
174.0, 173.1, 136.8, 135.0, 133.7, 132.7, 130.0, 129.6, 128.7, 128.2, 127.3, 126.7, 125.5, 
121.7, 98.3, 71.6, 69.7, 63.3, 54.9, 31.6, 29.8, 28.7. HRMS (ESI) calcd for 
C23H20LiN2O5
+
 (MLi
+
) 411.1527, found 411.1530. 
 
4.9b: 
 1
H NMR (500 MHz, CDCl3) δ 12.97 (s, 1H), 8.96 (dd, J = 
8.4, 1.2 Hz, 1H), 8.00 (dd, J = 8.0, 1.6 Hz, 1H), 7.66 (m, 1H), 
7.47 (dd, J = 8.1, 1.3 Hz, 1H), 7.35 (ddd, J = 8.7, 6.9, 2.0 Hz, 
1H), 7.26 (ddd, J = 8.4, 7.4, 1.2 Hz, 1H), 7.20 (dd, J = 8.0, 1.9 
Hz, 1H), 7.17 (ddd, J = 8.0, 6.9, 1.4 Hz, 1H), 6.75 (dd, J = 5.8, 
2.0 Hz, 1H), 5.70 (dd, J = 5.8, 1.1 Hz, 1H), 4.89 (dd, J = 2.0, 1.2 Hz, 1H), 4.67 (s, 1H), 
2.82 (dt, J = 17.1, 9.7 Hz, 1H), 2.71 (s, 3H), 2.64 (ddd, J = 17.4, 9.6, 1.7 Hz, 1H), 2.54 
(dt, J = 13.8, 9.8 Hz, 1H), 2.46 (ddd, J = 13.6, 9.1, 1.4 Hz, 1H). 
 13
C NMR (126 MHz, 
CDCl3) δ 201.8, 173.2, 171.1, 139.4, 137.1, 134.8, 134.0, 133.2, 131.7, 129.4, 128.6, 
128.4, 127.9, 127.8, 126.7, 123.4, 120.9, 104.1, 85.4, 85.1, 30.1, 28.8, 28.6. C23H21N2O5
+
 
(MH
+
) 405.1445, found 405.1461. 
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Irradiation of N-(2-(((2-acetyl-4-bromophenyl)carbamoyl)carbonyl)phenyl)-3-(furan-2-
yl)propanamide (4.7c): General procedure C was followed using 0.25 g of 4.7c (0.52 
mmol) in DCM (250 mL).  The mixture was purified by flash chromatography yielding 
pure 20-bromo-14,23-dihydroxy-23-methyl -2-oxa-7,16-
diazaheptacyclo[11.9.2.0
3,7
.0
3,25
.0
8,13
.0
16,24
.0
17,22
]pentacos-17(18),19(20),21(22)-
hexaene-6,15-dione (4.10c) (0.055 g, 21%), 5-(2-acetyl-4-bromophenyl)-2-oxa,5,14-
diaza-pentacyclo[10.5.1.0
1,14
.0
4,8
.0
8,13
]octadec-8(9),10(11),12(13)-triene-6,15-dione 
(4.11c) (0.033 g, 13%), and N‐(2‐acetyl-4-bromophenyl)‐12‐hydroxy‐4‐oxo‐16‐oxa‐5‐
aza-tetracyclo[11.2.1.0¹,⁵.0⁶,¹¹]hexadeca‐6,8,10,14‐tetraene‐12‐carboxamide (4.9c) 
(0.035 g, 14%). 
 
4.10c:  
1H NMR (500 MHz, DMSO) δ 8.31 (dd, J = 8.4, 1.2 Hz, 
1H), 8.08 (dd, J = 8.0, 1.6 Hz, 1H), 7.83 (d, J = 8.7 Hz, 1H), 
7.65 (d, J = 2.4 Hz, 1H), 7.49 (dd, J = 8.7, 2.4 Hz, 1H), 7.30 
(ddd, J = 8.4, 7.3, 1.7 Hz, 1H), 7.15 (ddd, J = 7.9, 7.2, 1.3 Hz, 
1H), 6.69 (s, 1H), 5.01 (s, 1H), 4.82 (dd, J = 7.3, 4.0 Hz, 1H), 
4.09 (d, J = 4.0 Hz, 1H), 3.26 (d, J = 6.9 Hz, 1H), 2.73 (m, 2H), 2.45 (m, 1H), 2.17 (ddd, 
J = 13.0, 10.5, 9.0 Hz, 1H), 1.49 (s, 3H). 
 13C NMR (126 MHz, DMSO) δ 174.8, 171.8, 
138.1, 133.7, 133.3, 130.8, 130.0, 129.6, 128.9, 126.1, 124.0, 123.4, 118.7, 118.1, 98.0, 
77.4, 72.0, 68.1, 60.2, 50.9, 32.1, 31.6, 30.4. HRMS (ESI) calcd for C23H19BrLiN2O5
+
 
(MLi
+
) 489.0632, found 489.0619. 
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4.11c: 
 1
H NMR (500 MHz, CDCl3) δ 8.31 (dd, J = 8.2, 1.3 Hz, 
1H), 8.00 (dd, J = 8.0, 1.5 Hz, 1H), 7.88 (d, J = 2.3 Hz, 1H), 7.69 
(dd, J = 8.4, 2.2 Hz, 1H), 7.46 (ddd, J = 8.2, 7.4, 1.5 Hz, 1H), 7.22 
(td, J = 7.7, 1.3 Hz, 1H), 7.02 (d, J = 8.4 Hz, 1H), 4.82 (ddd, J = 
9.2, 6.1, 4.6 Hz, 1H), 3.92 (dd, J = 10.0, 6.1 Hz, 1H), 3.87 (dd, J = 
10.1, 4.6 Hz, 1H), 3.66 (d, J = 9.1 Hz, 1H), 3.22 (s, 1H), 2.83 (dt, J = 17.2, 9.5 Hz, 1H), 
2.60 (s, 3H), 2.52 (ddd, J = 17.2, 9.5, 2.2 Hz, 1H), 2.45 (ddd, J = 13.2, 9.2, 2.2 Hz, 1H), 
2.33 (dt, J = 13.2, 9.7 Hz, 1H). 
 13C NMR (126 MHz, DMSO) δ 198.2, 173.5, 173.0, 
139.6, 135.0, 133.8, 133.7, 131.3, 129.2, 128.8, 128.2, 127.8, 124.5, 120.5, 120.4, 98.4, 
71.5, 68.0, 61.8, 53.7, 31.2, 29.9, 28.7. HRMS (ESI) calcd for C23H19BrLiN2O5
+
 (MLi
+
) 
489.0632, found 489.0617. 
 
4.9c: 
 1
H NMR (500 MHz, CDCl3) δ 12.88 (s, 1H), 8.90 (d, J = 
9.0 Hz, 1H), 8.08 (d, J = 2.4 Hz, 1H), 7.74 (dd, J = 9.0, 2.4 Hz, 
1H), 7.47 (dd, J = 8.0, 1.2 Hz, 1H), 7.35 (ddd, J = 8.1, 6.8, 2.0 
Hz, 1H), 7.16 (m, 2H), 6.72 (dd, J = 5.8, 2.0 Hz, 1H), 5.70 (dd, J 
= 5.8, 1.1 Hz, 1H), 4.97 (s, 1H), 4.87 (dd, J = 1.9, 1.1 Hz, 1H), 
2.74 (dd, J = 17.4, 9.8 Hz, 1H), 2.70 (s, 3H), 2.58 (m, 1H), 2.52 (dt, J = 13.8, 9.7 Hz, 1H) 
2.44 (ddd, J = 13.7, 9.3, 1.5 Hz, 1H). 
 13
C NMR (126 MHz, CDCl3) δ 200.6, 173.4, 171.3, 
138.3, 137.4, 136.9, 134.2, 133.8, 133.2, 129.3, 128.6, 128.5, 127.9, 126.7, 124.8, 122.6, 
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115.8, 104.1, 85.5, 85.1, 30.0, 28.8, 28.6.  HRMS (ESI) calcd for C23H19BrLiN2O5
+
 
(MLi
+
) 489.0632, found 489.0615. 
 
Irradiation of 3-(furan-2-yl)-N-(2-(((8-oxo-5,6,7,8-tetrahydronaphthalen-1-
yl)carbamoyl)carbonyl)phenyl)propanamide (4.7d): General procedure C was followed 
using  0.45 g of 4.7d (1.0 mmol) in DCM (200 mL).  Following the irradiation, the 
solution was concentrated to 25 mL, the mixture was centrifuged, the precipitate formed 
was filtered, washed with cold DCM (3 x 10 mL) followed by water (3 x 10 mL), and 
dried in a desiccator yielding pure 14,25-Dihydroxy-2-oxa-7,16-
diazaoctacyclo[12.11.2.1
17,21
.0
3,7
.0
3,27
.0
8,13
.0
16,26
.0
25,28
]octacos-
8(9),10(11),12(13),17(18),19(20),21(28)-hexaene-6,15-dione (4.10d) (0.15 g, 35%). The 
filtrate was purified by flash chromatography (DCM/MeOH) yielding pure 5-(8-Oxo-
5,6,7,8-tetrahydronaphthalen-1-yl)-2-oxa,5,14-diaza-
pentacyclo[10.5.1.0
1,14
.0
4,8
.0
8,13
]octadec-8(9),10(11),12(13)-triene-6,15-dione (4.11d) 
(0.10 g, 23%) and 12-Hydroxy-4-oxo-N-(8-oxo-5,6,7,8-tetrahydronaphthalen-1-yl)-
16-oxa-5-azatetracyclo[11.2.1.0¹,⁵.0⁶,¹¹]hexadeca-6,8,10,14-tetraene-12-carboxamide 
(4.9d) (0.052 g, 12%). 
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4.10d:  
1H NMR (500 MHz, DMSO) δ 8.22 (dd, J = 8.0, 1.6 Hz, 
1H), 8.20 (dd, J = 8.3, 1.3 Hz, 1H), 7.33 (ddd, J = 8.6, 7.4, 1.5 
Hz, 1H), 7.28 (m, 2H), 7.12 (ddd, J = 8.2, 7.3, 1.3 Hz, 1H), 7.03 
(dd, J = 7.1, 1.8 Hz, 1H), 6.50 (s, 1H), 4.62 (dd, J = 9.0, 6.7 Hz, 
1H), 4.13 (d, J = 6.7 Hz, 1H), 3.32 (d, J = 8.9 Hz, 1H), 3.25 (s, 
1H), 2.77 (dt, J = 17.0, 9.5 Hz, 1H), 2.67 (s, 2H), 2.55 (m, 1H), 2.46 (m, 1H), 2.33 (dt, J 
= 13.2, 9.7 Hz, 1H), 1.94 (m, 1H), 1.66 (m, 3H).
 13
C NMR (126 MHz, DMSO) δ 173.6, 
171.2, 139.2, 137.0, 133.3, 131.7, 129.4, 128.8, 128.2, 128.2, 127.2, 124.5, 122.1, 120.1, 
100.6, 81.7, 71.5, 66.6, 60.7, 52.4, 37.7, 32.0, 30.0, 29.2, 18.8. HRMS (ESI) calcd for 
C25H22LiN2O5
+
 (MLi
+
) 437.1683, found 437.1710. 
 
4.11d:  
1
H NMR (500 MHz, CDCl3) δ 8.33 (dd, J = 8.3, 1.2 Hz, 
1H), 8.14 (dd, J = 8.0, 1.6 Hz, 1H), 7.51 (t, J = 7.8 Hz, 1H), 7.44 
(ddd, J = 8.4, 7.4, 1.5 Hz, 1H), 7.38 (dd, J = 7.8, 1.2 Hz, 1H), 
7.22 (td, J = 7.7, 1.3 Hz, 1H), 6.97 (d, J = 7.7 Hz, 1H), 4.69 (m, 
1H), 3.86 (dd, J = 10.1, 4.0 Hz, 1H), 3.82 (dd, J = 10.1, 6.0 Hz, 
1H), 3.75 (d, J = 9.2 Hz, 1H), 3.48 (d, J = 2.3 Hz, 1H), 3.06 (m, 2H), 2.82 (dt, J = 17.2, 
9.5 Hz, 1H), 2.76 (m, 1H), 2.67 (ddd, J = 16.9, 7.8, 4.9 Hz, 1H), 2.52 (ddd, J = 17.2, 9.5, 
2.1 Hz, 1H), 2.43 (ddd, J = 13.2, 9.2, 2.2 Hz, 1H), 2.31 (dt, J = 13.2, 9.7 Hz, 1H), 2.17 
(m, 2H).  
13
C NMR (126 MHz, CDCl3) δ 198.0, 174.4, 173.2, 147.6, 137.0, 133.8, 133.6, 
130.4, 129.8, 128.5, 128.5, 127.4, 127.1, 125.4, 121.3, 98.4, 71.4, 69.2, 63.0, 54.9, 40.4, 
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31.2, 30.5, 29.8, 22.7.  HRMS (ESI) calcd for C25H22LiN2O5
+
 (MLi
+
) 437.1683, found 
437.1695. 
 
4.9d:  
1
H NMR (500 MHz, CDCl3) δ 13.40 (s, 1H), 8.83 (dd, J = 
8.4, 1.1 Hz, 1H), 7.54 (t, J = 8.0 Hz, 1H), 7.46 (dd, J = 8.0, 1.3 
Hz, 1H), 7.34 (ddd, J = 8.0, 7.0, 1.8 Hz, 1H), 7.20 (dd, J = 8.0, 
1.7 Hz, 1H), 7.16 (ddd, J = 8.1, 7.0, 1.4 Hz, 1H), 7.07 (dd, J = 
7.6, 1.0 Hz, 1H), 6.75 (dd, J = 5.8, 2.0 Hz, 1H), 5.70 (dd, J = 5.8, 
1.1 Hz, 1H), 4.89 (dd, J = 2.0, 1.1 Hz, 1H), 4.75 (s, 1H), 3.04 (t, J = 6.1 Hz, 2H), 2.80 
(dt, J = 17.2, 9.7 Hz, 1H), 2.74 (dd, J = 7.4, 5.7 Hz, 2H), 2.62 (ddd, J = 17.1, 9.6, 1.6 Hz, 
1H), 2.53 (dt, J = 13.9, 9.8 Hz, 1H), 2.45 (ddd, J = 13.8, 9.3, 1.6 Hz, 1H), 2.13 (p, J = 6.5 
Hz, 2H).  
13
C NMR (126 MHz, CDCl3) δ 202.3, 173.2, 171.2, 146.2, 140.4, 137.2, 134.7, 
134.1, 133.2, 129.5, 128.5, 128.3, 127.8, 126.7, 124.1, 119.7, 118.4, 104.1, 85.5, 85.2, 
40.7, 31.0, 30.1, 28.8, 22.7.  HRMS (ESI) calcd for C25H22LiN2O5
+
 (MLi
+
) 437.1683, 
found 437.1670. 
 
One pot procedure for the synthesis of 14,23-dihydroxy-23-methyl -2-oxa-7,16-
diazaheptacyclo[11.9.2.0
3,7
.0
3,25
.0
8,13
.0
16,24
.0
17,22
]pentacos-17(18),19(20),21(22)-
hexaene-6,15-dione (4.10b): 
 
Isatin (0.20 g, 1.4 mmol) was added to 3-(2-furyl)propionic acid (0.23 g, 1.6 
mmol) solution in DCM (10 mL) at 0 °C, followed by EDC (0.31 g, 1.6 mmol) and 
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DMAP (0.017 g, 0.14 mmol).  The reaction mixture was allowed to stir at room 
temperature for three hours.  The mixture was then treated with 2′-aminoacetophenone 
(0.22 g, 1.6 mmol) and stirred overnight.  After that, the mixture was diluted with DCM 
(50 mL) and washed with 5% aq.  HCl, water, a solution of sat. aq. NaHCO3, and water 
(25 mL each).  The organic layer was dried over Na2SO4, filtered, and concentrated.  The 
crude product was then dissolved in DCM (250 mL), degassed with N2 and irradiated in 
Pyrex or borosilicate glass reaction vessels in a Rayonet reactor equipped with RPR-3500 
UV lamps (broadband 300-400 nm UV source with peak emission at 350 nm) until 
consumption of the starting material and [4 + 2] cycloaddition products was observed, as 
determined by 1H NMR.  Following the irradiation, the solution was concentrated to 25 
mL, the mixture was centrifuged, the precipitate formed was filtered, washed with cold 
DCM (3 x 10 mL), followed by water (3 x 10 mL), and dried in a desiccator yielding pure 
4.10d (0.22, 39% over two steps). 
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Chapter 5: Conclusion 
 The synthetic utility of o-azaxylylene cycloadditions in the excited state has 
grown rapidly since this methodology was introduced in 2011,
20
 and will likely continue 
to grow at an even greater rate.  The excited state reaction pathway is no longer a black 
box, and has been shown to proceed through excitation to the singlet state, where ESIPT 
takes place, followed by intersystem crossing, an N-centered radical attack on the 
dienophile, and radical recombination yielding the [4 + 4] and [4 + 2] cycloaddition 
products.  This information will prove to be invaluable to those who utilize this 
methodology in the future.   
From this work it is clear that these cycloadditions follow the philosophy of 
diversity oriented synthesis, as they are capable of producing complex, and diverse 
scaffolds with good diastereoselectivity, and can probe an even greater region of 
chemical space, as these cycloaddition products are amenable to post-photochemical 
modifications such as palladium catalyzed cross coupling reactions. 
Cascade reactions involving o-azaxylylenes cores have been shown to yield fused 
sp
3
 cyclic systems containing multiple fused rings, chiral centers, hydrogen bond donors 
and acceptors, as well as few rotatable bonds keeping in keeping with the general 
characteristics of approved drug sources.
6
  These complex structures can be synthesized 
efficiently, as the photoprecursors can be obtained in a one-pot two-step reaction from 
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commercially available starting materials, and the [4 + 2]/[4 + 2] cascade products 
precipitate out of solution upon irradiation requiring no chromatographic purification. 
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Appendix B: List of Abbreviations  
 
Δ  temperature (heat) 
 
Φ  quantum yield 
 
Ac  acetyl 
 
ACN  acetonitrile  
 
aq.  aqueous  
 
Ar  aryl 
 
ca.  circa 
 
calcd  calculated 
 
cat.  catalyst (or catalytic amount) 
 
DCM  dichloromethane 
 
DFT  density functional theory 
 
DBU  1,8-diazabicyclo[5.4.0]undec-7-ene 
 
DIBAl-H diisobutylaluminum hydride 
 
DIPEA N,N-diisopropylethylamine 
 
DMAP  4-(dimethylamino)pyridine 
 
DME  dimethoxyethane  
 
DMF  dimethylformamide 
 
DMSO  dimethyl sulfoxide 
 
DOS  diversity oriented synthesis 
 
EDC  N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride 
 
ESIPT  excited state intramolecular proton transfer 
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Et  ethyl 
 
eq  equivalent 
 
FVT  flash vacuum thermolysis 
 
h  hour(s) 
 
hex  hexane 
 
HOMO highest occupied molecular orbital 
 
HPLC  high-performance liquid chromatography 
 
HRMS  high-resolution mass spectrum 
 
hν  light (irradiation) 
 
IPT  intramolecular proton transfer 
 
ISC  intersystem crossing 
 
Kdiff  rate of diffusion 
 
Ksv  Stern-Volymer constant 
 
LED  light emitting diode  
 
LUMO lowest unoccupied molecular orbital 
 
LC  liquid chromatography  
 
Me  methyl 
 
MIDA  N-methyliminodiacetic acid 
 
min  minute(s) 
 
MS  mass spectroscopy 
 
NMR  nuclear magnetic resonance 
 
NPMI  N-phenylmaleimide 
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P  product 
 
PCC  pyridinium chlorochromate 
 
PCy3  tricyclohexylphosphine 
 
Ph  phenyl 
 
i-Pr  iso-propyl 
 
Py  pyridine 
 
R  reactant 
 
RA  radical addition 
 
r.t.  room temperature 
 
S  goodness of fit 
 
S1  first singlet excited state 
 
sat.  saturated  
 
SOC  spin orbit coupling 
 
TCSPC time correlated single photon counting 
 
TEA  triethylamine 
 
THF  tetrahydrofuran 
 
TMS  trimethylsilane  
 
TOS  target oriented synthesis 
 
UV  ultraviolet 
 
 
 
 
 
  
